Subunit vaccines with A2 supermotifs

专利摘要:
A method of designing an effective vaccine in an individual carrying an A2 supertype allele is described. Single amino acid substitution homologues of known A2 supertype binding peptides, and large peptide libraries, are used to strictly define the peptide binding specificity of A2 supertype molecules. If each molecule has a unique preference, many overlaps in specificity are found. The presence of hydrophobic and aliphatic residues L, I, V, M, A, T and Q at position 2 of the peptide ligands is commonly tolerated by A2 supertype molecules. L, I, V, M, A and T are tolerated at the C-terminus. Investigation of secondary effects on peptide binding revealed allele specific preferences and shared features were also identified, which were used to define A2-supermotifs. Shared features also correlate with cross reactivity; It has been found that at least 70% of the peptides that bind A * 0201 with high affinity bind to two or more other A2 supertype molecules. Finally, coefficients are provided for use in developing an algorithm for the prediction of peptide binding to A2 supertype molecules.
公开号:KR20040052475A
申请号:KR10-2003-7010024
申请日:2002-01-29
公开日:2004-06-23
发明作者:시드니존；셋트알레싼드로；그레이하워드엠；사우쓰우드스코트
申请人:에피뮨 인코포레이티드；
IPC主号:

专利说明:

Subunit vaccines with A2 supermotifs
[2] The genetic makeup of a given mammal encodes the structure associated with the species' immune system. Although genetic diversity is great in the human population, there are common features and effects when comparing humans to other species. In mammals, feature molecules related to immune function are termed major histocompatibility complexes.
[3] MHC molecules are classified as type I or type II molecules. Type II MHC molecules are mainly expressed in cells involved in initiating and maintaining an immune response, such as T lymphocytes, B lymphocytes, macrophages and the like. Type II MHC molecules are recognized by helper T lymphocytes to induce the proliferation of helper T lymphocytes and amplification of the immune response to certain immunogenic peptides presented. Type I MHC molecules are expressed in almost all nucleated cells and are recognized by cytotoxic T lymphocytes (CTLs) and then destroy antigen-bearing cells. CTLs are particularly important in the treatment of tumor rejection and viral infections.
[4] CTLs recognize antigens in the form of peptide fragments bound to type I MHC molecules, rather than to intact foreign antigens themselves. Typically, the antigen must be endogenously synthesized by the cell, and the protein antigen portion is broken down into small peptide fragments in the cytoplasm. Some of these small peptides are transferred to the pre-Golgi compartment, interacting with the Type I heavy chain to promote proper folding and binding of the subunit β microglobulin. The peptide-MHC type I complex is then transferred to the cell surface for expression and potential recognition by specific CTLs.
[5] Examination of the crystal structure of the human MHC type I molecule, HLA-A2.1, revealed that the peptide binding grooves are formed by folding the α1 and α2 domains of the type I heavy chain (Bjorkman, et. al ., Nature 329: 506 (1987). However, in these investigations, the identity of the peptide bound to the grooves was not determined.
[6] Buus, et al ., Science 242: 1065 (1988) first described a method for acid elution of bound peptides from MHC. Lammensee and colleagues then developed a method for characterizing naturally processed peptides bound to type I molecules. Falk, et al ., Nature 351: 290 (1991). ]. Other researchers have also found that type A2.1 by mass spectrometry (Hunt, et al ., Science 225: 1261 (1992)), and type B (jardetzky, et al ., Nature 353: 326). (1991)] peptides eluted from type I molecules have successfully achieved direct amino acid sequencing of higher amounts of peptides in various HPLC fractions through conventional automated sequencing. The properties of naturally processed peptides in type I MHC are shown in the literature. Rotzschke & Falk, Immunol. Today 12: 447 (1991). PCT publication WO 97/34621, incorporated herein by reference, describes peptides with binding motifs for the A2.1 allele.
[7] See Sette, et al ., Proc. Nat'l. Acad. Sci . USA 86: 3296 (1989) shows that MHC allele specific motifs can be used to predict MHC binding capacity. See Schaeffer, et al ., Proc. Nat'l. Acad. Sci . USA 86: 4649 (1989) shows that MHC binding is associated with immunogenicity. See also De Bruijn, et al ., Eur. J. Immunol ., 21: 2963-2970 (1991); Pamer, et al ., 991 Nature 353: 852-955 (1991), provide preliminary evidence that type I binding motifs can be applied to the identification of potential immunogenic peptides in animal models. Type I motifs specific for a number of human alleles of a given type I isotype have not yet been described. The combination frequency of these different alleles will preferably be high enough to cover many or perhaps most of the human crossbreeding population.
[8] Despite advances in the art, the prior art has not yet provided useful human peptide-based vaccines or therapeutics based on these studies.
[9] summary
[10] The present invention provides parameters for the design of vaccines that are expected to effectively target the majority of the population. In accordance with the guidelines described herein, to prepare a vaccine for a particular infectious organism or virus or tumor, the relevant antigens are evaluated to determine the location of the epitope that is most likely to affect the cytotoxic T response to the infection or tumor. do. The amino acid sequences of the antigens of interest can be analyzed according to the methods described herein to identify appropriate sets of epitopes. Peptides consisting of these epitopes can be readily tested for their ability to bind one or more HLA alleles that are characteristic of the A2 supertype. In general, peptides that bind with an affinity of 500 nM or less are more likely to induce cytotoxic T lymphocyte (CTL) responses. The ability of these peptides to do this can be readily demonstrated. The vaccine can then be designed based on the immunogenic peptides identified as above. The vaccine itself may consist of the peptide itself, a precursor that is expected to produce the peptide in vivo, or a nucleic acid encoding these peptides for in vivo production.
[11] Thus, in one aspect, the present invention relates to a method for identifying epitopes in a characteristic antigen of a pathogen or tumor. The epitope identified by this method is more likely to augment an immune response in an individual carrying an allele of the A2 supertype than the peptide of choice for cancer. The method consists of 8 to 11 amino acids, wherein the amino acid at position 2 is small or aliphatic hydrophobic residue (L, I, V, M, A, T or Q) and the C-terminus is also small or aliphatic hydrophobic residue ( Analyzing the amino acid sequence of the antigen for an amino acid segment of L, I, V, M, A or T). In a preferred embodiment, the residue at position 2 is L or M. In another preferred aspect, the fragment contains 9 to 10 amino acids. In another preferred aspect, the fragment contains Q or N at position 1 and / or R, H or K at position 8 and lacks D, E and G at position 3, when the mer is demer It is. It is also preferred that the position 2 and the C-terminus are V.
[12] Also described herein are compositions comprising immunogenic peptides with binding motif subsequences for HLA-A2.1 molecules. Immunogenic epitopes in peptides that bind to the appropriate MHC allele are preferably 8 to 11 residues in length, more preferably 9 to 10 residues in length, and at specific positions such as position 2 and the C-terminus. It includes residues conserved in. The peptide may also be located at other positions, eg, positions 1, 3, 6 and / or 7 for peptides of 9 amino acids in length and positions 1, 3, 4, 5 for peptides of 10 amino acids in length. , 7, 8 and / or 9 do not include negative binding moieties as defined herein. The present invention defines a position in a motif that can select peptides that efficiently bind to HLA A2.1.
[13] Epitopes on many immunogenic target proteins can be identified using the sequence motifs described herein. Examples of suitable antigens include prostate cancer specific antigens (PSA), hepatitis B core and surface antigens (HBVc, HBVs), hepatitis C antigens, Epstein-Barr virus antigens, human immunodeficiency virus type 1 ( HIV 1), Kaposi's Sarcoma Herpes Virus (KSHV), Human Papilloma Virus (HPA) Antigen, Lassa Virus, Mycobacterium tuberculosis (MT), p53, CEA, Tripanosoma Surface Antigen (TSA) and Her2 / neu is included. The peptides and nucleic acids encoding them are useful in pharmaceutical compositions for in vivo and ex vivo therapeutic and diagnostic uses.
[14] Justice
[15] The term "peptide" is used interchangeably with "oligopeptide" herein and is a series of residues, typically L-, linked together by a peptide bond between the alpha-amino and carbonyl groups of adjacent amino acids. Point to amino acids. Oligopeptides are generally less than 250 amino acids in length and may be less than 150, 100, 75, 50, 25 or 15 amino acids in length. In addition, the oligopeptides of the invention do not comprise more than 15 contiguous amino acids of the natural antigen.
[16] The nomenclature used to describe the peptide compound is in accordance with conventional practice, where the amino group is shown to the left (N-terminus) of each amino acid residue and the carboxyl group is shown to the right (C-terminus). In the formulas representing certain selected embodiments of the present invention, amino- and carboxyl end groups are forms that they may take at physiological pH values, unless otherwise indicated, unless otherwise indicated. In amino acid structural formulas, each residue is generally represented by a standard three or one letter designation. L-forms of amino acid residues are indicated by the capital letter of the first letter or the first letter of the three letter symbol, and the D-types for these amino acids having the D-type are indicated by one letter of lowercase or three letters of lowercase. Glycine does not have asymmetric carbon atoms and is simply referred to as "Gly" or G.
[17] An “immunogenic peptide” or “epitope” is a peptide or amino acid sequence comprising an allele-specific motif, which peptide sequence can bind to MHC molecules and induce a CTL response. The immunogenic peptides of the invention can bind to appropriate HLA-A2 molecules and can induce cytotoxic T-cell responses against the antigen from which the immunogenic peptides are derived. Immunogenic peptides of the invention have a length of less than about 15 residues, often less than 12 residues, and typically consist of about 8 to about 11 residues, preferably 9 or 10 residues.
[18] Immunogenic peptides are conveniently identified using the algorithm of the present invention. This algorithm is a mathematical process that yields a score that enables the selection of immunogenic peptides. Typically, algorithm scores with “binding thresholds” are used that can select peptides that are likely to bind at a particular affinity and are still immunogenic. The algorithm is based on the effect on the MHC binding of specific amino acids at specific positions of peptides and on the binding of specific substitutions in motifs containing peptides.
[19] The binding result is often expressed as "IC ₅₀ ". IC ₅₀ is the concentration of peptide at which 50% inhibition of reference peptide binding is observed in the binding assay. Under the conditions under which the assay as described herein is performed (ie, restriction of HLA protein and labeled peptide concentration) these values are close to the K _D value. Assays for measuring binding are described in PCT publications WO 94/20127 and WO 94/03205. It should be noted that IC ₅₀ values can often vary dramatically depending on the particular reagent used (eg HLA preparation, etc.) when assay conditions vary. For example, excessive concentrations of HLA molecules increase the apparent IC ₅₀ measurements of a given ligand and thus do not reflect actual K _D values.
[20] Binding is often expressed in proportions relative to the reference peptide. As certain assays may be more or less sensitive, the IC ₅₀ of the peptide tested may vary somewhat. However, the binding to the reference peptide will not change significantly. For example, if the analysis is performed under conditions in which the IC ₅₀ of the reference peptide is increased by 10 times, the IC ₅₀ value of the test peptide will also change by about 10 times. Thus, to avoid ambiguity, evaluating whether a peptide is a good binder, an intermediate binder, a weak binder or a negative binder is generally based on the IC ₅₀ of the peptide relative to the IC ₅₀ of the standard peptide. This binding can be reported as a ratio or the ratio can be used to normalize the IC ₅₀ values described in Example 1.
[21] As used herein, high affinity for HLA type I molecules is defined as the binding of IC ₅₀ or K _D values of ₅₀ nM or less. Medium affinity is a binding of an IC ₅₀ (or K _D ) of about 50 to about 500 nM.
[22] A "conserved residue" is an amino acid that is present at a significantly higher frequency than would be expected by a random distribution at a particular position of the peptide. Typically conserved residues are those in which the MHC structure can provide a point of contact with an immunogenic peptide. One to three, preferably two conserved residues within the peptide of defined length define the motif for the immunogenic peptide. These residues are usually in intimate contact with the peptide binding grooves, and their side chains are buried in specific pockets of the grooves themselves. Typically, an immunogenic peptide will contain up to three conserved residues, more typically two conserved residues.
[23] As used herein, a “negative binding moiety”, when present at a specific position (eg, positions 1, 3, and / or 7 of the hexamer), produces a peptide that is a non-binding or poor binding agent, resulting in immunogenicity. Loss, ie, induce a CTL response.
[24] The term "motif" refers to a pattern of residues in a peptide of defined length, typically about 8 to about 11 amino acids, which is recognized by certain MHC alleles. These peptide motifs are typically different for each human MHC allele and differ in the pattern of highly conserved residues and negative residues.
[25] Binding motifs for alleles can be defined with increased accuracy. In one example, all conserved residues are at the correct position in the peptide and there are no negative residues at positions 1, 3 and / or 7.
[26] A "supermotif" is a peptide binding specificity shared by an HLA molecule encoded by two or more HLA alleles. Supermotif-bearing epitopes are preferably recognized as high affinity (as defined herein) or medium affinity by two or more HLA antigens.
[27] As used herein, “HLA supertype or family” refers to a set of HLA molecules classified based on shared peptide-binding specificity. HLA type I molecules that share somewhat similar binding specificities for peptides having specific amino acid motifs are classified as HLA supertypes. The terms HLA superfamily, HLA supertype family, and HLA xx-like supertype molecules, where xx refers to a specific HLA type, are synonymous.
[28] The expression "isolated" or "biologically pure" refers to a substance which, when found in its natural state, is substantially or essentially free of components that normally accompany it. Thus, the peptides of the present invention do not contain substances that are commonly bound in their in situ environment, such as MHC type I molecules on antigen presenting cells. Even when the proteins are separated into homogeneous or superior bands, trace contaminants are present in the range of 5-10% of the native protein co-purified with the desired protein. Isolated peptides of the present invention do not contain such endogenous co-purified proteins.
[29] The term "residue" refers to an amino acid or amino acid mimetic inserted into an oligopeptide by an amide bond or an amide bond mimetic.
[1] Subjects described herein relate to the design of a vaccine that is effective for most of the members of a population, particularly the population characterized by having the A2 allele. Subunit vaccines containing A2 supermotifs can be designed to be applicable to such populations.
[30] 1 . Position 2 and C-terminal microspecificity of HLA-A * 0201. The preference for a particular residue at position 2 (a) or C-terminus (b) is shown as a function of% peptide having a specific residue that binds A * 0201 with an IC50 of at least 500 nM. The ARB value of a peptide having a particular residue at position 2 (a) or C-terminus (b) is calculated as described herein and indexed based on the residue with the highest binding capacity. The average (geometric) binding capacity of the peptide with L at position 2 is 1991 nM. The average (geometric) binding capacity of the peptide with V at the C-terminus is 2133 nM. Peptides included in the assay, at position 2 or C-terminus, have one or more commonly used anchor residues as described herein.
[31] 2 . Map of A * 0201 motifs. Summary map of A * 0201 motifs for 8-mer (b), 10-mer (c) and 11-mer (d) peptides. At secondary anchor positions, residues that appear to be preferred (or deleterious) are bound with an average binding capacity of at least three times or more (or three times or less) than peptides of the same size having other residues at the same position. In the primary anchor position, preferred residues are those residues that bind at the same position with an average binding capacity within 10 times the optimal residue. Common primary anchor residues are those residues that bind at the same position with an average binding capacity of 10 to 100 times the optimal residue.
[32] 3 . Position 2 microspecificity of the HLA-A2-supertype molecule. The ARB value of a peptide having a specific residue at position 2 is calculated for each A2-supertype molecule as described herein and indexed based on the residue with the highest ARB for each specific molecule. do. The average (geometric) binding capacity of the peptide with the residue with the highest ARB is 55, 59, 89 and 41 nM for A * 0202, A * 0206, and A * 6802, respectively.
[33] 4 . C-terminal microspecificity of HLA-A2-supertype molecule. ARB values of peptides having specific residues at the C-terminus are calculated for each A2-supertype molecule as described herein, and the index is based on the residue with the highest ARB for each specific molecule. Write. The average (geometric) binding capacity of the peptide with the residue with the highest ARB is 291, 48, 250 and 553 nM for A * 0202, A * 0203, A * 0206, and A * 6802, respectively.
[34] 5 . Map of A * 0202 motifs. Summary map of A * 0202 motifs for 9-mer (a) and 10-mer (b) peptides. At secondary anchor positions, residues that appear to be preferred (or deleterious) are bound with an average binding capacity of at least three times or more (or three times or less) than peptides of the same size having other residues at the same position. In the primary anchor position, preferred residues are those residues that bind at the same position with an average binding capacity within 10 times the optimal residue. Commonly used first anchor residues are those residues that bind at the same position with an average binding capacity of 10 to 100 times the optimal residue.
[35] 6 . Map of A * 0203 motifs. Summary map of A * 0203 motifs for 9-mer (a) and 10-mer (b) peptides. At secondary anchor positions, residues that appear to be preferred (or deleterious) are bound with an average binding capacity of at least three times or more (or three times or less) than peptides of the same size having other residues at the same position. In the primary anchor position, preferred residues are those residues that bind at the same position with an average binding capacity within 10 times the optimal residue. Commonly used first anchor residues are those residues that bind at the same position with an average binding capacity of 10 to 100 times the optimal residue.
[36] 7 . Map of A * 0206 motifs. Summary map of A * 0206 motifs for 9-mer (a) and 10-mer (b) peptides. At secondary anchor positions, residues that appear to be preferred (or deleterious) are bound with an average binding capacity of at least three times or more (or three times or less) than peptides of the same size having other residues at the same position. In the primary anchor position, preferred residues are those residues that bind at the same position with an average binding capacity within 10 times the optimal residue. Common primary anchor residues are those residues that bind at the same position with an average binding capacity of 10 to 100 times the optimal residue.
[37] 8 . Map of A * 6802 motif. Summary map of A * 6802 motifs for 9-mer (a) and 10-mer (b) peptides. At secondary anchor positions, residues that appear to be preferred (or deleterious) are bound with an average binding capacity of at least three times or more (or three times or less) than peptides of the same size having other residues at the same position. In the primary anchor position, preferred residues are those residues that bind at the same position with an average binding capacity within 10 times the optimal residue. Commonly used first anchor residues are those residues that bind at the same position with an average binding capacity of 10 to 100 times the optimal residue.
[38] 9 . A2 supertype consensus summaries of the secondary and primary anchors affect the A2-supertype binding capacity of the 9-mer (a) and 10-mer (b) peptides. The residues shown significantly affect binding to three or more A2-supertype molecules. The number of molecules affected is shown in parentheses. At secondary anchor positions, residues that do not deleteriously affect one or more molecules are considered preferred. Preferred residues harmful for one molecule are indicated in reduced italic type. Evaluation at the primary anchor position is based on single substitution and peptide library analysis as described herein.
[39] The present invention relates in part to an epitope-based approach for vaccine design. This approach is based on the well-established finding that the mechanism inducing a CTL immune response involves presenting a CTL epitope as a peptide of about 8 to 11 amino acids bound to an HLA molecule displayed on an antigen-presenting cell. do. HLA molecules are the product of type I MHC, which is expressed in most nucleated cells.
[40] The products of MHC type I alleles are generally characterized as A, B and C HLA molecules. Within each of these categories, there are multiple allelic variants in the population; In fact, it is believed that there are well over 500 type I and II alleles. Since no cytotoxic T-cell response can be induced unless an epitope is presented by the type I HLA contained on the cell surface of the individual to be immunized, the epitope is capable of binding to the HLA exhibited by the individual. It is important to be.
[41] Thus, a starting point for designing effective vaccines is to establish that the vaccine produces a number of epitopes that can be successfully presented. It is also possible to administer peptides which are epitopes themselves. Such administration is dependent on the presentation of "empty" HLA molecules appearing on the subject cells. In an approach using the immunogenic peptides themselves, these peptides can be incubated with antigen-presenting cells from a subject to be treated ex vivo, and then the cells can be put back into the subject.
[42] Alternatively, 8-11 amino acid peptides can be generated in situ by administering a nucleic acid containing a nucleotide sequence encoding it. Means for providing such nucleic acid molecules are described in WO 99/58658, incorporated herein by reference. Immunogenic peptides can also be administered as part of a larger peptide molecule and cleaved to release the desired peptide. Larger peptides may contain exogenous amino acids, but fewer are better. Thus, peptides containing such amino acids typically consist of up to 25 amino acids, more typically up to 20 amino acids, even more typically up to 15 amino acids. In addition, the precursor may be a heteropolymer or homopolymer containing multiple different or identical CTL epitopes. Of course, mixtures of nucleic acids and peptides that produce a variety of immunogenic peptides can be used. The design of peptide vaccines, nucleic acid molecules, or hetero- or homo-polymers depends on the content of the desired epitope. The present invention provides a paradigm for identifying relevant epitopes that are effective against a broad population of individuals characterized by the A2 supertype. Experimental methods and results for the identification of A2 super motifs are described below.
[43] It is preferred that the peptide comprises an epitope that binds to the HLA-A2 supertype allele. These motifs define T-cell epitopes from any desired antigen, in particular those associated with human viral disease, cancer or autoimmune disease (the amino acid sequence of a potential antigen or autoantigen target thereof is known). Can be used.
[44] Epitopes on many potential target proteins can be identified based on HLA binding motifs. Examples of suitable antigens include prostate specific antigens (PSA), hepatitis B core and surface antigens (HBVc, HBVs), hepatitis C antigens, Epstein-Barr virus antigens, melanoma antigens (e.g., MAGE- 1), human immunodeficiency virus (HIV) antigen, human papilloma virus (HPV) antigen, p53, CEA, tripanosoma surface antigen (TSA) and Her2 / neu.
[45] Peptides comprising epitopes from these antigens are synthesized, for example by immunofluorescence staining and flow microfluorescence analysis, peptide-dependent type I assembly assays, and inhibition of CTL recognition by peptide competition, for example. In assays using cells expressing purified type I molecules and radioiodide peptides and / or empty type I molecules, the appropriate MHC molecules are tested for their ability to bind. These peptides that bind type I molecules are furthermore not only capable of being used as targets for CTLs derived from individuals infected or immunized, but also to react with target cells or tumor cells infected by the virus as potential therapeutic agents. Can be assessed for the ability to induce a primary ex vivo or in vivo CTL response that can generate a population of CTLs.
[46] MHC type I antigens are encoded by HLA-A, B and C loci. HLA-A and B antigens are expressed on the cell surface at approximately the same density, while the expression of HLA-C is significantly lower (possibly 10-fold lower). Each of these loci has a number of alleles. The peptide binding motifs of the invention are relatively specific for each allele subtype.
[47] In the case of peptide-based vaccines, preferably the peptide comprises a motif recognized by a MHC type I molecule having a wide distribution in the human population, or includes a motif recognized genetically by various populations. Since MHC alleles appear at different frequencies within different ethnic groups and races, the choice of target MHC allele can be determined according to the target population. Table 1 shows the frequency of various alleles in the HLA-A left product among different races. For example, the majority of the Caucasian population may be covered by peptides that bind to four HLA-A allele subtypes, specifically HLA-A2.1, A1, A3.2, and A24.1. Similarly, the majority of the Asian population includes the addition of peptides that bind the fifth allele HLA-A11.2.
[48]
[49] This table is described in B. DuPont, Immunobiology of HLA , Vol. I, Histocompatibility Testing 1987, Springer-Verlag, New York 1989].
[50] * N = black race; A = Asian; C = Caucasian. The number in parentheses indicates the number of individuals included in the analysis.
[51] Cross reactive binding of HLA-A2.1 motif-bearing peptides with other HLA-A2 allele-specific molecules can occur. These allele-specific molecules that share binding specificity with HLA-A2.1 are thought to include the HLA-A2.1 supertype. The B format of the A2 supertype HLA molecule consists of residues F / Y ₉ , A ₂₄ , M ₄₅ , E / N ₆₃ , K / N ₆₆ , V ₆₇ , H / Q ₇₀ and Y / C ₉₉ (this nomenclature is one letter). Amino acid code is used, where the subscripts indicate the position of the peptide). Similarly, the A2-supertype F format is characterized by a consensus motif comprising residues D ₇₇ , T ₈₀ , L ₈₁ and Y ₁₁₆ (155). About 66% of the peptide binding A * 0201 will be cross-reactive among three or more A2-supertype alleles.
[52] The A2 supertype as defined herein is a living cell binding assay [del guercio, M.-F. et al. , J. Immunol. 154: 685, 1995]. Cross-reactivity data from Fruci, D. et al. , Hum. Immunol . 38: 187, 1993, and data obtained by sequencing naturally processed peptides bound to HLA-A2 allele-specific molecules (Sudo, T., et al ., J. Immunol. 155: 4749, 1995]. Thus, the family of HLA molecules (ie, the HLA-A2 supertype that binds these peptides) consists of at least nine HLA-A proteins: A * 0201, A * 0202, A * 0203, A * 0204, A * 0205, A * 0206, A * 0207, A * 6802, and A * 6901.
[53] As described herein, the HLA-A2 super motif has L, I, V, M, A, T, or Q as the primary anchor residue at position 2 of the epitope and has a primary anchor residue at the C-terminus. As peptide peptides having L, I, V, M, A, or T. The HLA-A2 motif most particularly related to the invention claimed herein includes V, A, T or Q at position 2 and L, I, V, M, A, or T at C-terminal anchor position. . Peptide epitopes comprising the HLA-A2 super motif may bind to one or more HLA-A2 supertype molecules.
[54] Methods that can be used to identify peptides of the present invention are described in Fallk, et al ., Nature 351: 290 (1991), incorporated herein by reference. In summary, the method involves the large-scale separation of MHC type I molecules, usually by immunoprecipitation or affinity chromatography, from appropriate cells or cell lines. Examples of other methods for isolating MHC molecules of interest, which are likewise well known to those skilled in the art, include ion exchange chromatography, lectin chromatography, size exclusion, high performance ligand chromatography, and any combination of the above techniques.
[55] In conventional cases, immunoprecipitation can be used to isolate the desired allele. Depending on the specificity of the antibody used, numerous protocols can be used. For example, allele-specific mAb reagents can be used for affinity purification of HLA-A, HLA-B and HLA-C molecules. Several mAb reagents can be used to separate HLA-A molecules. Monoclonal BB7.2 is suitable for separating HLA-A2 molecules. Affinity columns made with these mAbs using standard techniques are successfully used to purify each HLA-A allele product.
[56] In addition to allele-specific mAbs, broadly reactive anti-HLA-A, B, C mAbs, such as W6 / 32 B9.12.1 and B1.23.2, are described in other affinity purification protocols described in the Examples below. Can be used for
[57] Peptides bound to the peptide binding grooves of the isolated MHC molecules are typically eluted using acid treatment. Peptides can also be dissociated from type I molecules using various standard denaturation means, such as heat, pH, detergents, salts, chaotropic agents, or combinations thereof.
[58] Peptide fractions are further separated from MHC molecules by reversed phase high performance liquid chromatography (HPLC) and sequenced. Peptides can be separated by various other standard means well known to those skilled in the art, such as filtration, ultrafiltration, electrophoresis, size chromatography, precipitation with specific antibodies, ion exchange chromatography, isoelectrofocusing, and the like. have.
[59] Sequencing of isolated peptides can be accomplished by Edman digestion (Hunkapiller, MW, et al ., Methods Enzymol . 91, 399 (1983). Another suitable method for sequencing is mass spectrometry to sequence individual peptides as described previously . See Hunt, et al. Science 225: 1261 (1992); Incorporated herein by reference]. Amino acid sequencing of bulky heterologous peptides (eg, collected HPLC fractions) from different Type I molecules typically shows characteristic sequence motifs for each Type I allele.
[60] By defining motifs specific for different type I alleles, one can identify potential peptide epitopes from known antigenic proteins with amino acid sequences. Typically, identification of potential peptide epitopes is first performed using a computer to scan the amino acid sequence of the antigen of interest for the presence of the motif.
[61] After identification of the motif-bearing epitope, epitope sequences are synthesized. The ability to bind MHC type molecules is measured in a variety of different ways. One means is a type I molecular binding assay as described in the relevant section below. Another alternative described in the literature is the inhibition of antigen presentation [Sette, et al ., J. Immunol . 141: 3893 (1991)], in vitro assembly assays (Townsend, et al., Cell 62: 285 (1990)) and FACS utilization assays using mutated cells such as RMA.S [Ref. Melief, et al ., Eur. J. Immunol . 21: 2963 (1991).
[62] As described herein, higher HLA binding affinity correlates with greater immunogenicity. Greater immunogenicity can be manifested in several different ways. Immunogenicity corresponds to whether the immune response is induced and the intensity of the particular response as well as the extent of the various populations from which the response is induced. For example, peptides can induce an immune response in a diverse array of populations, but so far no strong response has occurred. According to the principles described herein, close to 90% of high binding peptides have been found to be immunogenic, while about 50% of peptides bind with moderate affinity. In addition, higher binding affinity peptides induce more potent immunogenic responses. As a result, when high affinity binding peptides are used, less peptides are required to induce similar biological effects. Thus, in a preferred embodiment of the present invention, high affinity binding epitopes are particularly useful. Nevertheless, significant improvements over the prior art have been achieved using medium or high binding peptides.
[63] The relationship between binding affinity for HLA type I molecules and immunogenicity of discrete peptide epitopes was first determined by the inventors in the art. In these experiments using discrete peptides, even if long chain fragments are used, these peptides will be induced due to peptide cell processing in vivo. Thus, long chain peptides comprising one or more epitopes are within the scope of the present invention. The correlation between binding affinity and immunogenicity was analyzed by two different experimental methods . Sette, et al., J. Immunol. 153: 5586-5592, 1994]. In the first method, the immunogenicity of a potential epitope with an HLA binding affinity of more than 10,000 fold was analyzed in HLA-A * 0201 transgenic mice. In a second method, the antigenicity of about 100 different hepatitis B (HBV) -derived potential epitopes (all with A * 0201 binding motifs) using PBL (peripheral blood lymphocytes) from acute hepatitis patients Evaluated. According to these methods, it was determined that affinity threshold values of about 500 nM (preferably 50 nM or less) correlated with the ability of peptide epitopes to induce CTL responses. These data are true for the determination of type I binding affinity for naturally processed peptides and synthesized T-cell epitopes. In addition, these data show an important role of determinant selection in realizing T-cell responses. See Schaeffer, et al., Proc. Natl. Acad. Sci. USA 86: 4649-4653, 1989].
[64] Thus, CTL-derived peptides preferably include those having an IC ₅₀ of 500 nM or less for type I HLA molecules. In the case of motif-bearing peptide epitopes from tumor-associated antigens, it was found that the binding affinity threshold of 200 nM is associated with the death of tumor cells by the formation of CTL populations.
[65] In a preferred embodiment, after assessing the binding activity for the HLA-A2 allele-specific molecule, peptides exhibiting high or moderate affinity are considered for further analysis. The selected peptide is tested to see if it is another member of the supertype family. In a preferred embodiment, peptides exhibiting cross-reactive binding are used for vaccine or cell screening assays.
[66] For example, peptides tested positive in HLA-A2 binding assays, ie, having binding affinity values of 500 nM or less, are evaluated for their ability to induce specific CTL responses in vitro. For example, antigen-presenting cells incubated with peptides can be assessed for their ability to induce CTL responses in reactor cell populations. Antigen-presenting cells may be normal cells, such as peripheral blood mononuclear cells or dendritic cells. Inaba, et al ., J. Exp. Med. 166: 182 (1987); Boog, Eur. J. Immunol. 18: 219 (1988).
[67] Alternatively, mouse cell line RMA-S [Karre, et al ., Nature , 319: 675 (1986); Ljunggren, et al ., Eur. J. Immunol . 21: 2963-2970 (1991), and human body cavity T-cell hybrids, T-2 (Cerundolo, et al ., Nature 345: 449-452 (1990)). Mutant mammalian cell lines lacking the ability to load type I molecules and transfected with suitable genes encoding human type I molecules induce primary CTL responses in vitro when peptides are added to them externally It can be conveniently used to test the ability to do so. Other eukaryotic cell lines that can be used include various insect cell lines, such as mosquito larvae (ATCC cell lines CCL 125, 126, 1660, 1591, 6585, 6586), silkworms (ATCC CRL 8851), armyworm (ATCC CRL). 1711), moths (ATCC CCL 80) and Drosophila cell lines (eg Schneider cell line) [Schneider J. Embryol. Exp. Morphol . 27: 353-365 (1927).
[68] Peripheral blood lymphocytes are conveniently isolated after simple venipuncture or leukapheresis in normal donors or patients and used as a reactor cell source of CTL precursors. In one embodiment, the appropriate antigen-presenting cells are incubated with 10-100 μM peptides in serum-free medium for 4 hours under appropriate culture conditions. The peptide-loaded antigen-presenting cells are then incubated with the reactor cell population in vitro for 7-10 days under optimal culture conditions. Positive CTL activation kills both radiolabeled target cells, i.e., target cells expressing specific peptide-pulsed targets as well as endogenously processed forms of the relevant virus or tumor antigen from which the peptide sequence is derived. Can be measured by analyzing the culture for the presence of.
[69] Specificity and MHC restriction of CTLs are determined by testing target cells expressing human MHC type I, either appropriate or inappropriate for different peptides. Peptides tested positive in MHC binding assays and eliciting specific CTL responses are referred to herein as immunogenic peptides.
[70] Kats, et al ., J. Immunol. 152: 3904-3912, 1994, suggests that motif-bearing peptides reach 90% of epitopes that bind to allele-specific HLA type I molecules. In this study, all possible peptides (240 peptides) with 9 amino acids in length and 8 amino acids overlapping (which covers the entire sequence of E6 and E7 proteins of human papillomavirus type 16) were selected from different ethnic groups. Binding to five allele-specific HLA molecules expressed at frequencies was assessed. The unbiased set of these peptides can be used to estimate the expected value of the HLA type I motif. From 240 peptide sets, 22 peptides were identified that were linked to allele-specific HLA molecules with high or moderate affinity. Twenty (ie 91%) of these 22 peptides possessed the motif. Thus, these studies demonstrated motif values for the identification of peptide epitopes to be included in the vaccine; Screening of potential epitopes 90% was eliminated by applying motif-based identification techniques. Given the amount of peptides available and the complexity of the screening, it will be appreciated that without the use of the motif the evaluation of the antigen would be very difficult if not impossible.
[71] Immunogenic peptide epitopes of the invention can be included in polyepitope vaccine compositions comprising additional peptide epitopes of the same antigen, antigens from the same source and / or antigens from different sources. In addition, type II epitopes may be included with type I epitopes. Peptide epitopes from the same antigen may be contiguous epitopes with consecutive sequences or may be obtained from different regions of a protein.
[72] As described in more detail below, immunogenic peptides may be prepared synthetically, for example by chemical synthesis or recombinant DNA techniques, or may be isolated from natural sources such as complete viruses or tumors. Although it is desirable for the peptide to be substantially free of other proteins and fragments thereof from the natural host cell, in some embodiments, the peptide can be synthesized by conjugation to natural fragments or particles.
[73] The polypeptide or peptide may vary in length, may be in neutral (uncharged) form or in salt form, lacks modifications such as glycosylation, branched chain oxidation or phosphorylation, or the modifications are biological activities of the polypeptide described herein. These modifications may be contained under conditions that do not destroy
[74] Preferably, the peptide will be as small as possible while still substantially maintaining the biological activity of the large peptide. If possible, it would be desirable to optimize the peptide epitopes of the invention to lengths of 9 or 10 amino acid residues corresponding to the size of endogenously processed viral peptides or tumor cell peptides bound to MHC type I molecules on the cell surface. will be.
[75] Peptides with the desired activity provide at least all biological activity that allows the unmodified peptide to bind to the desired MHC molecule to activate the appropriate T-cell, while providing the specific properties of interest, e.g., improved pharmacological characteristics. Modifications may be made if necessary to substantially maintain or increase. For example, the peptide may undergo various changes, such as conservative or non-conservative substitutions, and such changes may provide certain advantages of these uses, such as improved MHC binding. Conservative substitutions mean substituting an amino acid residue for another biologically and / or chemically similar residue, for example, replacing a hydrophobic residue with another hydrophobic residue, or a polar residue with another polar residue. Such substitutions include Gly, Ala; Val, Ile, Leu, Met; Asp, Glu; Asn, Gln; Ser, Thr; Lys, Arg; And combinations such as Phe, Tyr. The effect of single amino acid substitutions can be examined using D-amino acids. Such modifications can be made using well known peptide synthesis procedures. See Merrifield, Science 232: 341-347 (1986), Barany and Merrifield, The Peptides, Gross and Meienhofer, eds. (N.Y., Academic Press), pp. 1-284 (1979); and Stewart and Young, Solid Phase Peptide Synthesis, (Rockford, Ill., Pierce), 2d Ed. (1984)].
[76] The peptide can be modified by stretching or decreasing the amino acid sequence of the compound, for example by addition or deletion of amino acids. Peptides or homologues of the invention can be modified by altering the order or composition of certain residues, and certain amino acid residues essential for biological activity, such as residues or conserved residues of indispensable contact sites, generally do not adversely affect biological activity. It cannot be changed without it. Non-indispensable amino acids need not be limited to naturally occurring residues in the protein, such as L-α-amino acids, but may be used as well as non-natural amino acids such as β-γ-δ-amino acids, as well as D- And many derivatives of L-α-amino acids, such as isomers.
[77] Typically, a series of peptides with single amino acid substitutions are used to measure the effects of electrostatic charge, hydrophobicity, and the like on binding. For example, a series of positively charged (eg Lys or Arg) or negatively charged (eg Glu) amino acid substitutions can be made along the length of the peptide and exhibit different patterns of susceptibility to various MHC molecules and T-cell receptors. . In addition, multiple substitutions using small, relatively neutral residues (eg, Ala, Gly, Pro) or similar residues may be used. Such substitutions may result in multi-epitopeptide peptides that are homo-oligomers or hetero-oligomers. The number and type of residues to be substituted and added is determined by the spacing required between the required contact point and the particular functional attribute (eg hydrophobic versus hydrophilic) desired. In addition, compared to the affinity of the parent peptide, increased binding affinity for MHC molecules or T-cell receptors can be achieved by such substitutions. In any case, such substitutions generally use amino acid residues or other molecular fragments selected to avoid steric and charge disturbances that may destroy, for example, a bond.
[78] Amino acid substituents are typically single residues. Substitutions, deletions, insertions or any combination thereof can be combined to obtain the final peptide. Substitution variants are those wherein one or more residues of the peptide have been removed and different residues inserted therein. If you wish to fine tune the characteristics of the peptides, such substitutions are generally made according to Table 2 below.
[79]
[80] Substantial changes in function (e.g., affinity for MHC molecules or T-cell receptors) may be achieved by selecting substitutions that are less conservative than those illustrated in Table 2, namely (a) the structure of the peptide backbone in the substitution region, eg For example in sheet or spiral form, (b) the charge or hydrophobicity of the molecules at the target site, or (c) their effect on maintaining the size of the side chains can be obtained by selecting residues that are significantly different. Substitutions that are generally expected to cause maximum changes in peptide properties include (a) hydrophilic residues (eg, seryl) being substituted with hydrophobic residues (eg, leusil, isoleucyl, phenylalanyl, valelyl or alanyl) (B) a residue with a positively charged side chain (such as lysyl, arginyl or histidyl) is replaced with a negatively charged residue (such as glutamyl or aspartyl), or (c) a residue with a large side chain (E.g., phenylalanyl) will be substituted with residues without side chains (e.g. glycine).
[81] In addition, the peptides include isosteres of two or more residues of an immunogenic peptide. Isosteast as defined herein is a sequence of two or more residues that can be substituted with a second sequence because the conformation of the first sequence is consistent with the specific binding site for the second sequence. The term specifically encompasses peptide backbone modifications that are well known to those skilled in the art. Such modifications include modifications of amide nitrogen, α-carbon, amide carbonyl, complete replacement of amide bonds, elongation, deletion or backbone crosslinking. See Spatola, Chemistry and Biochemistry of Amino Acids, Peptides and Proteins, Vol. VII (Weinstein ed., 1983)].
[82] Modifications of peptides with various amino acid mimetics or non-natural amino acids are particularly useful for increasing the stability of peptides in vivo. Stability can be assessed in a number of ways. For example, the stability was tested using peptidase and various biological media such as human plasma and serum. Verhoef, et al ., Eur. J. Drug Metab. Pharmacokin. 11: 291-302 (1986). The half-life of the peptides of the invention is conveniently determined using 25% human serum (v / v) assay. The protocol is generally as follows. Lipids are removed by centrifugation before using the collected human serum (Type AB, non-heat inactivated). Serum is then diluted to 25% using RPMI tissue culture medium and used to test peptide stability. At predetermined time intervals, a small amount of the reaction solution is removed and added to 6% aqueous trichloroacetic acid or ethanol. The cloudy reaction sample is cooled (4 ° C.) for 15 minutes and then pelleted by spinning the precipitated serum protein. The presence of the peptide is then determined using reverse phase HPLC under stability-specific chromatography conditions.
[83] Modifications of the peptides of the invention or their analogs with CTL stimulatory activity provide the desired properties other than improved serum half-life. For example, the ability of a peptide to induce CTL activity can be enhanced by linking to sequences containing one or more epitopes capable of inducing T helper cell responses.
[84] In some embodiments, the T helper peptide is one recognized by T helper cells in most populations. This is accomplished by selecting amino acid sequences that bind to many, most or all of the MHC type II molecules. These are known as "loosely MHC-limited" T helper sequences. Examples of loosely MHC-restricted amino acid sequences include: tetanus toxin (QYIKANSKFIGITE) at positions 830-843, Plasmodium falciparum (CS) protein (DIEKKIAKMEKASSVFNVVNS) at positions 378-398, and Sequences from antigens such as Streptococcus 18 kD protein (YGAVDSILGGVATYGAA) at positions 1-16 are included.
[85] Alternatively, amino acid sequences not found in nature may be used to prepare synthetic peptides that can stimulate T helper lymphocytes in a loosely MHC-limited manner. These synthetic peptides, called Pan-DR-binding epitopes or PADRE ^™ molecules [Epimmune, San Diego, CA], are designed based on their binding activity to most HLA-DR (human MHC type II) molecules. : US Pat. No. 5,736,142].
[86] Particularly preferred immunogenic peptide / T helper conjugates are linked by spacer molecules. Such spacers typically consist of relatively small, neutral molecules such as amino acids or amino acid mimetics that do not substantially change under physiological conditions. The spacer is typically selected from Ala, Gly or nonpolar amino acids or neutral polar amino acids. It is understood that the optionally present spacers need not be composed of identical residues, and therefore may be hetero- or homo-oligomers. If present, the spacer will typically be at least 1 or 2 residues, more typically 3 to 6 residues. Alternatively, CTL peptides can be linked to T helper peptides without spacers.
[87] The immunogenic peptide may be linked to the T helper peptide either directly or through a spacer at the amino or carboxy terminus of the CTL peptide. The amino terminus of the immunogenic peptide or T helper peptide may be acylated. Examples of T helper peptides include tetanus modified toxin 830-843, influenza 307-319, malaria spores 382-398 and 378-389.
[88] In some embodiments, it will be desirable to include one or more ingredients in the pharmaceutical compositions of the present invention that prime CTLs. Lipids have been identified as agents capable of first stimulating CTLs in vivo against viral antigens. For example, palmitic acid residues may be attached to the alpha and epsilon amino groups of lysine residues and then linked to immunogenic peptides via one or more linking residues, such as Gly, Gly-Gly-, Ser, Ser-Ser, and the like. Can be. Lipidated peptides can then be injected directly in the form of micelles, incorporated into liposomes, or emulsified in an adjuvant such as an incomplete Freund's adjuvant. In a preferred embodiment, particularly effective immunogens include palmitic acid attached to the alpha and epsilon amino groups of Lys, which are linked to the amino terminus of the immunogenic peptide via a linkage (eg, Ser-Ser).
[89] As another example of lipids that stimulate the CTL response, E. coli lipoproteins such as trippalmitoyl-S-glycerylcysteineriseryl-serine (P ₃ CSS) can be used to first stimulate virus specific CTLs when covalently bound to appropriate peptides. Deres, et al ., Nature 342: 561-564 (1989). Peptides of the invention can be coupled to, for example, P ₃ CSS, and the lipopeptides can be administered to a subject to specifically stimulate the CTL response to a target antigen. In addition, since the induction of neutralizing antibodies can be first stimulated with P ₃ CSS conjugated to a peptide showing a suitable epitope, the two compositions can be combined to more effectively induce both humoral and cell-mediated responses to infection. can do.
[90] In addition, additional amino acids can be added to the ends of the peptides to facilitate linkages between the peptides, to couple to a carrier support or a large peptide, and to modify the physical or chemical properties of the peptide or oligopeptide. Amino acids such as tyrosine, cysteine, lysine, glutamic acid or aspartic acid, etc. can be introduced at the C- or N-terminus of the peptide or oligopeptide. In some cases, modifications at the C-terminus can alter the binding characteristics of the peptide. In addition, the peptide or oligopeptide sequence may be modified by terminal-NH ₂ acylation such as alkanoyl (C1-C20) or thioglycoyl acetylation, terminal-carboxyl amidation such as ammonia, methylamine, or the like. It may differ from the native sequence. In some instances, these modifications provide a site for linking to a support or other molecule.
[91] Peptides of the invention can be prepared in a wide variety of ways. Because of their relatively short size, the peptides (discontinuous epitopes or polyepitopeptide peptides) can be synthesized in solution or on a solid support according to conventional techniques. Various automated synthesizers are commercially available and can be used according to known protocols. Stewart and Young, Solid Phase Peptide Synthesis, 2d. ed. , Pierce Chemical Co. (1984), supra].
[92] Alternatively, the preparation of the peptides of the present invention involves recombinant DNA technology in which a nucleotide encoding a desired immunogenic peptide is inserted into an expression vector, introduced into a suitable host cell, transformed or transfected, and cultured under conditions suitable for expression. It may include the use of. These procedures are generally known in the art and are generally described in Sambrook, et al ., Molecular Cloning, A Laboratory Manual, Cold Spring Harbor Press , Cold Spring Harbor, New York (1982). Is described. Thus, fusion proteins comprising one or more peptide sequences of the invention can be used to present a suitable T-cell epitope.
[93] Coding sequences for peptides of length contemplated herein can be found in chemical techniques, eg, Matteucci, et al ., J. Am. Chem. Soc . 103: 3185 (1981), the modifications can be made simply by substituting the base encoding the natural peptide sequence with the appropriate base (s). The linker is then provided with the appropriate linker, linked to an expression vector commercially available in the art, and then transformed with a suitable host to produce the desired fusion protein. Many such vectors and suitable host systems are currently available. For expression of the fusion protein, the coding sequence is provided with operably linked initiation and termination codons, promoter and terminator regions, and the replication system is typically provided with expression vectors for expression in the host cell of interest. For example, plasmids containing appropriate restriction sites for insertion of the desired coding sequence are provided with promoter sequences suitable for bacterial hosts. The resulting expression vector is introduced into a suitable bacterial host and transformed. Of course, yeast or mammalian cell hosts can also be used when using suitable vectors and regulatory sequences.
[94] The peptides of the present invention and pharmaceutical and vaccine compositions thereof are useful for the therapeutic treatment and / or prevention of infections and cancers by administration to mammals, especially humans. Examples of diseases that can be treated using the immunogenic peptides of the present invention include prostate cancer, hepatitis B, hepatitis C, AIDS, renal carcinoma, cervical carcinoma, lymphoma, CMV infectious disease and cusp condyloma.
[95] In the case of pharmaceutical compositions, the immunogenic peptides of the invention are often administered to a subject already suffering from or infected with the virus. Individuals in the latent or acute phase of infection can be treated using only immunogenic peptides or optionally in combination with other therapeutic agents. In therapeutic use, the composition is administered to a patient in an amount sufficient to induce an effective CTL response to an infectious disease agent or tumor antigen to treat or at least partially arrest symptoms and / or complications. Appropriate amounts to accomplish this are defined as "therapeutically effective amounts" or "unit dosages." The amount effective for this use will depend, for example, on the peptide composition, the mode of administration, the stage and severity of the disease to be treated, the body weight and general health of the patient, and the findings of the attending physician. In general, for humans, the dosage range for initial immunization (ie for therapeutic or prophylactic administration) ranges from about 1.0 μg to about 20,000 μg of peptide, preferably 100 μg-, 150 μg-, for 70 kg patients, 200 μg-, 250 μg-, 300 μg-, 400 μg-, or 500 μg-20,000 μg, and then measure the specific CTL activity in the patient's blood to boost over weeks to months depending on the patient's response and condition ( Boosting is administered in the same dosage range according to the boosting method. In embodiments where recombinant nucleic acid administration is used, the administered material is titrated to obtain the appropriate therapeutic response. It should be noted that, in general, the peptides and compositions of the present invention may be used in severe disease states, i.e. life threatening or potentially life threatening. In such cases, given the minimization of the exogenous material in the compositions of the present invention and the relatively nontoxic properties of the peptides in question, for example, the attending physician may think that these compositions can be administered in large excess and that this is desirable.
[96] In case of therapeutic use, administration should be started immediately after initial diagnosis of the infection, upon detection or surgical removal of the tumor, or immediately after diagnosis in the case of acute infection. The boosting administration is then performed at least until the symptoms are substantially alleviated and for a period of time. In the case of chronic infections, boosting administration is required following loading administration.
[97] When treating an infected individual with the compositions of the present invention, it is possible to speed up the resolution of the infection in an acutely infected individual. In the case of individuals prone to (or tend to) develop chronic infections, the compositions are particularly useful in methods for preventing the progression from acute infections to chronic infections. For example, as described herein, when individuals susceptible to infection prior to or during an infection are identified, the compositions can target them, thus minimizing the need to administer to large populations.
[98] In addition, the peptide composition can be used for the treatment of chronic infections and can be used to stimulate the immune system to remove, for example, virus-infected cells in carriers. It is important to provide sufficient amounts of immune-enhancing peptides in certain formulations and modes of administration to effectively stimulate cytotoxic T-cell responses. Thus, in the treatment of chronic infections, boosting administration at established intervals (eg, 1 to 4 weeks) after immunization administration may be required for a long period of time in order to effectively immunize an individual. In the case of chronic infections, administration should continue until clinical signs or laboratory tests indicate that the infection has been eliminated or substantially alleviated, and for a period of time thereafter.
[99] Pharmaceutical compositions for therapeutic treatment are administered parenterally, topically, orally or topically. Peptides of the invention can be administered in the form of nucleic acids encoding the peptide. Preferably, the pharmaceutical composition is administered parenterally, for example intravenously, subcutaneously, intradermal, or intramuscularly. Accordingly, the present invention provides compositions for parenteral administration comprising a solution of an immunogenic peptide dissolved or suspended in an acceptable carrier, preferably an aqueous carrier. Various aqueous carriers can be used, such as water, buffered water, 0.8% saline, 0.3% glycine, hyaluronic acid, and the like. These compositions may be sterilized by conventional, well known sterilization techniques or may be sterile filtered. The resulting aqueous solution can be packaged or lyophilized for use as is and the lyophilized formulation is combined with a sterile solution prior to administration. The compositions may be used as pharmaceutically acceptable auxiliary substances required to resemble physiological conditions, such as pH adjusters and buffers, tonicity adjusters, wetting agents, etc., for example sodium acetate, sodium lactate, sodium chloride, potassium chloride, calcium chloride, Sorbitan monolaurate, triethanolamine oleate and the like.
[100] The concentration of CTL stimulatory peptides of the present invention in pharmaceutical formulations varies widely, ie, from less than about 0.1 weight percent, typically from about 2 weight percent or at least about 2 weight percent to 20 to 50 weight percent and more. Depending on the particular mode of administration chosen, it will primarily be chosen by flow rate, viscosity, and the like. Typically, the human unit dosage form of the peptide composition is included in a pharmaceutical composition comprising a human unit dosage of an acceptable carrier, preferably an aqueous carrier, and known to those skilled in the art used to administer such a composition to a human. Is administered at a flow rate.
[101] In addition, the peptides of the present invention can be administered via liposomes, which not only target the peptide to specific tissues, such as lymphoid tissues, or selectively target infected cells, but also increase the half-life of the peptide composition. Contribute to. Liposomes include emulsions, foams, micelles, insoluble monolayers, liquid crystals, phospholipid dispersions, lamellar layers, and the like. In these formulations, the peptide to be administered is part of a liposome, alone or in combination with other therapeutic or immunogenic compositions, such as monoclonal antibodies that bind to a receptor that is predominant in lymphoid cells, such as a CD45 antigen. It is incorporated as. Thus, liposomes filled with or added to the peptide of interest of the present invention can be directed to the site of lymphoid cells, where the liposomes deliver the selected therapeutic / immunological peptide composition. Liposomes for use in the present invention are generally formed from standard vesicle-forming lipids, including neutral and negatively charged phospholipids and sterols such as cholesterol. In general, the selection of lipids is made in consideration of liposome size, acid instability, and stability of liposomes in the bloodstream. Various methods for the preparation of liposomes can be used. See Szoka, et al ., Ann. Rev. Biophys. Bioeng . 9: 467 (1980), US Pat. Nos. 4,235,871, 4,501,728, 4,837,028, and 5,019,369.
[102] To target immune cells, the ligands to be incorporated into liposomes can include, for example, antibodies or fragments thereof specific for the cell surface determinants of the immune system cells of interest. Liposomal suspensions containing peptides can be administered intravenously, topically, topically, and the like, in particular depending on the mode of administration, the peptide to be administered, and the condition of the condition being treated.
[103] For solid compositions, conventional non-toxic solid carriers can be used, including, for example, pharmaceutical grade mannitol, lactose, starch, magnesium stearate, sodium saccharin, talc, cellulose, glucose, sucrose, magnesium carbonate and the like. . For oral administration, any of the commonly used excipients, for example the carriers described above, and generally the concentration of 10 to 95%, more preferably 25% to 75% of the active ingredient, ie one or more peptides of the invention, are incorporated. To obtain a pharmaceutically acceptable non-toxic composition.
[104] For aerosol administration, preferably the immunogenic peptide is supplied in finely divided form with a surfactant and propellant. Typically, the percentage of peptide is 0.01% to 20% by weight, preferably 1% to 10% by weight. Of course, the surfactant should be nontoxic and preferably soluble in propellants. Representative examples of such agents include esters or partial esters of fatty acids having 6 to 22 carbon atoms, for example caproic acid, octanoic acid, lauric acid, palmitic acid, stearic acid, linoleic acid with aliphatic polyhydric alcohols or cyclic anhydrides thereof. , Linolenic acid, olesteric acid, and oleic acid. Mixed esters may be used, for example mixed or natural glycerides. The surfactant constitutes 0.1% to 20%, preferably 0.25% to 5% by weight of the composition. The remainder of the composition is a conventional propellant. If desired, lecithin is used, for example for intranasal administration, if a carrier can be included.
[105] Thus, one aspect of the present invention relates to a vaccine containing as an active ingredient an immunologically effective amount of an immunogenic peptide described herein. In addition, the peptide may be administered in the form of a nucleic acid expressed in the receptor, encoding the peptide of the invention. The peptide (s) may be linked to its own carrier or introduced into a host, including human, as a homopolymer or heteropolymer of active peptide units. Such polymers have the advantage that the immunological response is increased, different peptides are used to prepare the polymer, and have the additional ability to induce antibodies and / or CTLs that react with different antigenic determinants of virus or tumor cells. Useful carriers are well known in the art, examples of which include tyroglobulin, albumin (eg human serum albumin), tetanus toxin, polyamino acids (eg poly (lysine: glutamic acid)), influenza. Hepatitis B virus core protein, hepatitis B virus recombinant vaccine, and the like. In addition, the vaccine may contain a physiologically tolerated (acceptable) diluent such as water, phosphate buffered saline, or saline, and further typically comprises an adjuvant. Materials such as unstable Freund's adjuvant, aluminum phosphate, aluminum hydroxide, or alum are well known in the art as adjuvant. As mentioned above, the CTL reaction can be first stimulated by conjugating a peptide of the invention to a lipid (eg, P ₃ CSS). When a peptide composition as described herein is immunized by injection, aerosol, oral, transdermal or other route, the host's immune system responds to the vaccine by producing large amounts of CTLs specific for the antigen of interest, and the host It is at least partially immunized against subsequent infections or resistant to progression to chronic infections.
[106] In some instances, it may be desirable to combine the peptide vaccines of the invention with vaccines that induce neutralizing antibody responses against the virus in question, particularly viral envelope antigens.
[107] For treatment or immunization, the peptides of the invention can be administered in the form of nucleic acids encoding one or more peptides of the invention. The nucleic acid may encode the peptide of the invention and optionally one or more additional molecules. Numerous methods are conveniently used to administer nucleic acids to patients. For example, nucleic acids can be administered directly as "naked DNA". Such methods are described, for example, in Wolf, et al., Science 247: 1465-1468 (1990), and US Pat. Nos. 5,580,859 and 5,589,466. Nucleic acids can also be administered using ballistic delivery, as described, for example, in US Pat. No. 5,204,253. Particles consisting solely of DNA can be administered. Alternatively, DNA can be adsorbed to particles such as golden particles.
[108] The nucleic acid may also be administered in complex with a cationic compound, such as a cationic lipid. Lipid-mediated gene delivery methods are described, for example, in WO 96/18372; WO 93/24640; Mannino & Gould-Fogerite, BioTechniques 6 (7): 682-691 (1988); Rose, US Pat. No. 5,279,833; WO 91/06309; And Felgner, et al., Proc. Natl. Acad. Sci. USA 84 : 7413-7414 (1987).
[109] In addition, the peptides of the present invention may be expressed by an attenuated viral host, for example vaccinia or fowlpox virus. Such methods include the use of vaccinia virus as a vector expressing a nucleotide sequence encoding a peptide of the invention. When introduced into an acute or chronically infected or uninfected host, the recombinant vaccinia virus expresses an immunogenic peptide, thereby inducing a host CTL response. Vaccinia vectors and methods useful in immunization protocols are described, for example, in US Pat. No. 4,722,848. Another vector is BCG (Bacille Calmette Guerin). BCG vectors are described, for example, in Stover, et al., Nature 351: 456-460 (1991). A wide variety of vectors useful for the therapeutic administration or immunization of the peptides of the invention, such as Salmonella typhi vectors, and the like, will be apparent to those skilled in the art from the present disclosure.
[110] Preferred means of administering a nucleic acid encoding a peptide of the present invention employ minigene constructs encoding the multiple epitopes of the present invention, optionally in combination with other molecules. To prepare a DNA sequence encoding a CTL epitope (minigene) selected for expression in human cells, the amino acid sequence of that epitope is for example reversely decoded. The codon utilization table is used to select codons for each amino acid. These epitope-encoding DNA sequences are immediately contiguous, resulting in molecules that encode contiguous polypeptide sequences. Optionally, additional elements can be introduced into the minigene design to optimize expression and / or immunogenicity. Examples of amino acid sequences that are reverse translated and may be included in the minigene sequence include helper T lymphocyte epitopes, leader (signal) sequences, vesicle residual signals. In addition, MHC presentation of CTL epitopes can be enhanced by including synthetic (eg poly-alanine) or natural flanking sequences adjacent to the CTL epitopes.
[111] The minigene sequence is converted into DNA by assembling oligonucleotides encoding the (+) and (-) strands of the minigene. Overlapping oligonucleotides (30-100 bases in length) are synthesized, phosphorylated, purified and annealed under appropriate conditions using well known techniques. The ends of the oligonucleotides are linked using T4 DNA ligase. This synthetic minigene, which encodes a CTL epitope polypeptide, is then cloned into the desired expression vector.
[112] Standard regulatory sequences that are well known to those of skill in the art are generally included in vectors for expression in target cells. Several vector elements are required: downstream-cloning sites for promoter and minigene insertion; Polyadenylation signals for efficient transcription termination; E. coli replicants; E. coli screening markers (eg ampicillin or kanamycin resistance). For this purpose a number of promoters can be used, for example human cytomegalovirus (hCMV) promoters. See US Pat. Nos. 5,580,859 and 5,589,466 for other suitable promoter sequences.
[113] Additional vector modifications may be required to optimize minigene expression and immunogenicity. In some cases, introns may be required for efficient gene expression, and one or more synthetic or natural introns may be inserted into the transcription region of the minigene. In order to increase the expression of minigenes, one may consider including mRNA stabilizing sequences. It has recently been proposed that immunostimulatory sequences (ISSs or CpGs) play a role in the immunogenicity of DNA vaccines. These sequences can be included outside the minigene coding sequence within the vector, if found to enhance immunogenicity.
[114] In some aspects, bicistronic expression vectors can be used that allow the production of minigene-encoded epitopes and a second protein included to increase or decrease immunogenicity. Examples of proteins or polypeptides that, when co-expressed, can advantageously increase the immune response include cytokines (eg, IL2, IL12, GM-CSF), cytokine-inducing molecules (eg, LeIF) or costimulatory molecules do. In addition, when helper T lymphocyte (HTL) epitopes are used, HTL epitopes are linked to intracellular target signals and expressed separately from CTL epitopes. The HTL epitope is thus directed to a cell compartment different from the CTL epitope. This allows HTL epitopes to enter the MHC type II pathway more efficiently, thus promoting and improving CTL induction. Unlike CTL induction, it may be beneficial in certain diseases to specifically reduce the immune response by co-expression of immunosuppressive molecules such as TGF-β.
[115] Once the expression vector is selected, the minigene is cloned downstream of the polylinker region of the promoter. These plasmids are introduced into suitable E. coli strains and transformed, and DNA is prepared using standard techniques. The orientation and DNA sequence of the minigene as well as all other elements included in the vector are confirmed using restriction mapping and DNA sequence analysis. Bacterial cells bearing the correct plasmids are stored as master cell banks and working cell banks.
[116] The therapeutic amount of plasmid DNA can be obtained, for example, by purification after fermentation of E. coli. Aliquots from working cell banks are used to inoculate fermentation medium (eg, Terrific Broth) and grown until saturated in a shaker flask or viro reactor according to well known techniques. Plasmid DNA is purified using standard bioseparation techniques, such as solid phase anion-exchange resin (Quiagen). If desired, ultra-helix DNA can be isolated from ring-opening or linear using gel electrophoresis or other methods.
[117] Purified plasmid DNA can be prepared for injection using various formulations. The simplest of these is the reconstitution of lyophilized DNA in sterile phosphate-buffered saline (PBS). Various methods have been described and new techniques may be used. As noted above, nucleic acids can be conveniently formulated using cationic lipids. In addition, glycolipids, fusogenic liposomes, peptides, and compounds collectively referred to as protective, interactive, non-condensable (PINC) also form complexes with purified plasmid DNA to provide stability, intramuscular dispersibility, or It may affect variables such as trafficking to specific tissues or cell types.
[118] Target cell sensitization can be used as a functional assay for the expression of minigene-encoded CTL epitopes and MHC type I presentation. Plasmid DNA can be introduced into a suitable mammalian cell line as a target for standard CTL chromium release assays. The transfection method used may vary depending on the final formulation. Electrophoresis can be used for “naked” DNA, while direct in vitro transfection can be performed using cationic lipids. Plasmids expressing green fluorescent protein (GFP) can be co-transfected to accumulate transfected cells using fluorescence activated cell sorting (FACS). These cells are then chromium-51 labeled and used as target cells for epitope-specific CTL lines. Cytolysis detected by 51Cr release indicates the generation of MHC presentation of minigene-encoded CTL epitopes.
[119] In vivo immunogenicity is the second approach to test the function of minigene DNA formulations. Transgenic mice expressing suitable human MHC molecules can be immunized with the DNA product. Dosage and route of administration are determined by formulation (eg, IM for DNA in PBS, IP for DNA complexed with lipids). 21 days after immunization, splenocytes are harvested and re-stimulated for one week in the presence of a peptide encoding each epitope under test. These effector cells (CTLs) are analyzed using standard techniques for cytolysis of peptide-loaded, chromium-51 labeled target cells. DNA vaccine function for in vivo induction of CTLs is demonstrated from lysis of target cells sensitized by loading peptides corresponding to minigene-encoded epitopes into MHC.
[120] Suitable haplotype transgenic animals provide useful means for optimizing the immunogenicity of minigene DNA in vivo. In addition, human immunogenicity of CTL epitopes can be measured using animals such as monkeys with conserved HLA molecules that are cross reactive to CTL epitopes recognized by human MHC molecules . Bertoni, et al. , J. Immunol . 161: 4447-4455 (1998).
[121] These in vivo studies account for important variables in the development of vaccines that cannot be readily evaluated by in vitro assays, such as the route of administration, vaccine formulation, tissue biodistribution, and the relevance of primary and secondary lymphoid organs. Is required. Because of their simplicity and adaptability, HLA transgenic mice offer an attractive alternative, at least in early vaccine development, to laborious and costly studies with higher animal species such as non-human primates.
[122] Antigenic peptides can also be used to induce CTLs in vitro. The CTL obtained can be used to treat chronic infections (eg viruses or bacteria) or tumors in patients who do not respond to other conventional treatment forms or do not respond to peptide vaccine therapy. In vitro CTL responses to specific pathogens (infectious agents or tumor antigens) are induced by incubating the patient's CTL precursor cells (CTLp) with a source of antigen-presenting cells (APC) and appropriate immunogen peptides in tissue culture. After a suitable antigenic treatment period (typically one to four weeks) at which CTLp is activated, matured, and augmented with effector CTL, the cells are reintroduced into the patient, whereby their specific target cells (infected cells or tumor cells) Will destroy.
[123] The peptide can also be used as a diagnostic reagent. For example, the peptides of the present invention can be used to determine the susceptibility of a particular subject to a treatment method using the peptide or related peptides, and thus can be useful for modifying current treatment protocols or for determining the prognosis of an infected subject. have.
[124] For example, the peptides of the invention can be used in tetramer staining assays that evaluate peripheral blood mononuclear cells for the presence of antigen-specific CTLs after exposure to pathogens or immunogens. HLA-tetramer complexes can be used to directly visualize antigen-specific CTL [Ogg, et al. Science 279: 2103-2106, 1998; and Altman, et al. Science 174: 94-96, 1996, and can also be used to determine the frequency of antigen-specific CTL populations in samples of peripheral blood mononuclear cells. Tetramer reagents using the peptide of the present invention can be prepared as follows. Peptides that bind to allele-specific HLA molecules or supertype molecules are refolded in the presence of the corresponding HLA heavy chain and β ₂ -microglobulin to generate trimolecular complexes. The complex is biotinylated at the carboxyl terminus of the heavy chain of the site previously introduced into the protein by genetic engineering. Streptavidin is then added to induce tetramer formation. With fluorescence labeled streptavidin, this tetramer can be used to stain antigen-specific cells. The cells can then be identified, for example, by flow cytometry. Such assays can be used for diagnostic or prognostic purposes.
[125] In addition, the peptides can be used to predict whether a subject is at substantial risk of developing a chronic infection.
[126] This application is filed on Jan. 23, 1996, now abandoned, and is a continuation of US Patent Application Serial No. 08 / 89,108, filed Mar. 5, 1993, and now abandoned: US Patent No. 08 / 027,146, 1993 Partial sequential applicant of US Patent Application No. 08 / 073,205, filed June 4 and now abandoned, Part sequential applicant of U.S. Patent Application 08 / 159,184, filed November 29, 1993, now abandoned, 3 1994 US Patent Application Serial No. 08 / 205,713, filed May 4. This application is also filed March 21, 1996 and is now abandoned US Patent Application 60 / 013,980, US Patent Application 08 / 454,033, filed May 26, 1995, December 2, 1994 US patent application Ser. No. 08 / 349,177, filed on January 27, 1996, and now abandoned, is hereby incorporated. The above mentioned applications are each incorporated herein by reference.
[127] Example 1: Peptides
[128] The peptide used was synthesized as described previously in Ruppert, J. et al ., "Prominent Role of Secondary Anchor Residues in Peptide Binding to HLA-A2.1 Molecules," Cell 74: 929-937 (1993). Or as crude material from the source [Chiron Mimotopes (Chiron Corp., Australia)]. Typically, the synthesized peptide was purified to> 95% homogeneity by reverse phase HPLC. Purity of the synthesized peptides was determined using analytical reversed phase HPLC and amino acid analysis, sequencing, and / or mass spectrometry. The lyophilized peptide was resuspended at 4-20 mg / ml in 100% DMSO and then diluted to the required concentration in PBS + 0.05% (v / v) NP40 (Fluka Biochemika, Buchs, Switzerland).
[129] Example 2 MHC Tablets
[130] EBV transformed cell lines JY (A * 0201), M7B (A * 0202), FUN (A * 0203), DAH (A * 0205), CLA (A * 0206), KNE (A * 0207), AP (A * 0207), and AMAI (A * 6802) were used as the primary source of MHC molecules. A single MHC allele-transfected 721.221 cell line was also used as a source of A * 0202 and A * 0207. Cells were RPMI supplemented with 2 mM L-glutamine (GIBCO, Grand Island, NY), 100 U (100 mg / ml) penicillin-streptomycin solution (GIBCO) and 10% heat-inactivated FCS (Hazelton Biologics) Cultured in 1640 medium (Flow Laboratories, McLean, VA) was maintained in vitro. Large scale cultures were maintained in a roller bottle. HLA molecules were purified from cell lysates (Sidney, J., et al ., "The Measurement of MHC / Peptide Interactions by Gel Infiltration," Curr Prot Immunol 18.3.1-18.3.19 (1998)). . In summary, cells are lysed at a concentration of 10 ⁸ cells / ml in 50 mM Tris-HCL, pH 8.5, containing 1% (v / v) NP-40 150 mM NaCl, 5 mM EDTA, and 2 mM PMSF. I was. The lysate was then passed through a 0.45 μM filter, centrifuged at 10,000 × g for 20 minutes to remove nuclei and byproducts, and the MHC molecules were purified by monoclonal antibody-based affinity chromatography.
[131] For affinity purification, columns of inactivated Sepharose CL4B and Protein A Sepharose were used as pre-columns. Type I molecules were captured by repeated passage through the protein A Sepharose beads conjugated with anti-HLA (A, B, C) antibody W6 / 32. [Sidney, J., et al ., Supra ]. HLA-A molecules were further purified from HLA-B and -C molecules by passing through a B1.23.2 column. After two to four passes, the W6 / 32 column was passed a 10-column amount of 10 mM Tris-HCL (pH 8.0) containing 1% (v / v) NP-40, a 2-column amount of PBS, and Washed with a 2-column amount of PBS containing 0.4% (w / v) n-octylglucoside. Type I molecules were eluted with 50 mM dimethylamine in 0.15 M NaCl (pH 11.5) containing 0.4% (w / v) n-octylglucoside. A 1/26 volume of 2.0 M Tris (pH 6.8) was added to the eluate to reduce the pH to ˜8.0. The eluate was then concentrated by centrifugation at 2000 rpm with a Centriprep 30 concentrator (Amicon, Beverly, Mass.). Protein purity, concentration, and effect of the depletion step were monitored by SDS-PAGE and BCA analysis.
[132] Example 3 MHC-Peptide Binding Assay
[133] Quantitative analysis to determine the binding of peptides to soluble type I molecules utilizes the inhibition of radiolabeled standard peptides. These analyzes were performed as previously described (Sidney, J., et al ., Supra). In summary, 1-10 nM of the radiolabelled peptide was combined with 1 μM to 1 nM of purified MHC in the presence of a cocktail of 1 μM human β ₂ -microglobulin (Scripps Laboratories, San Diego, Calif.) And protease inhibitors at room temperature. Co-incubated together. After two days of incubation,% MHC bound radioactivity was determined by size exclusion gel filtration chromatography using a TSK 2000 column. Alternatively,% MHC bound radioactivity was captured by capturing the MHC / peptide complex on a W6 / 32 antibody-coated plate and measuring bound cpm using a TopCount microscintillation counter (Packard Instrument Co., Meriden, CT). It was measured by the method (Southwood, et al ., Epimmune Technical Report Epi 063-99).
[134] The radiolabeled standard peptides used for the A * 0201, A * 0202, A * 0203, A * 0205, A * 0206, and A * 0207 analyzes were F ₆ > Y homologs of the HBV core 18-27 epitope (SEQ ID NO: FLPSDYFPSV). This was. The average IC ₅₀ of this peptide for each molecule was 5.0, 4.3, 10, 4.3, 3.7, and 23 nM, respectively. C ₄ > A homologues of HBV pol 646 (SEQ ID NO: FTQAGYPAL), or MAGE 1 282 (SEQ ID NO: YVIKVSARV) were used as markers for A * 6802 analysis. Their IC ₅₀ for A * 6802 were 40 and 8 nM, respectively.
[135] For competitive assays, concentrations of peptides that inhibit the binding of radiolabeled peptides by 50% were calculated. Peptides were initially tested at 1 or 2 times higher doses. The IC ₅₀ of the peptide showing positive inhibition was then measured in subsequent experiments in which 1 to 6 additional dilutions were tested. Under the conditions used, where [label] <[MHC] and IC ₅₀ ≧ [MHC], the measured IC ₅₀ value is a reasonable estimate of the actual Kd value. Each competitor peptide was tested in two to four independent experiments. As a positive control, an unlabeled form of radiolabeled probe was tested in each experiment.
[136] Example 4: Alternative Binding Assay
[137] Epstein-Barr virus (EBV) -transformed homozygous cell lines, fibroblasts, CIR, or 721.22 transfectants were used as a source of HLA type I molecules. These cells were treated with 2 mM L-glutamine (GIBCO, Grand Island, NY), 50 mM 2-ME, 100 mg / ml streptomycin, 100 U / ml penicillin (Irvine Scientific) and 10% heat-inactivated FCS (Irvine Scientific , Santa Ana, CA) was incubated in RPMI 1640 medium supplemented and maintained in vitro. Cells were grown in 225-cm ² tissue culture flasks or in a rotary bottle apparatus for large scale culture. The cells were harvested by centrifugation at 1500 RPM with an IEC-CRU5000 centrifuge with 259 rotors and washed three times with phosphate buffered saline (PBS) (0.01 M PO ₄ , 0.154 M NaCl, pH 7.2).
[138] Cells were pelleted and stored at −70 ° C. or treated with detergent lysates to obtain detergent lysates. Cell lysates were prepared using 1% NP-40 (Sigma) or Renex 30 (Accurate Chem. Sci. Corp., Westbury, NY 11590), 150 mM NaCl, 50 mM Tris, pH 8.0]. Obtained by addition to cell pellets (already counted) at a rate of 50-100 × 10 ⁶ cells. A cocktail of protease inhibitors was added to a pre-measured amount of detergent stock just prior to addition to the cell pellet. By adding the protease inhibitor cocktail, the following final concentrations were obtained: phenylmethylsulfonyl fluoride (PMSF), 2 mM; Aprotinin, 5 μg / ml; Leupeptin, 10 μg / ml; Pepstatin, 10 μg / ml; Iodoacetamide, 100 μM; And EDTA, 3 ng / ml. Cell lysis proceeded at 4 ° C. for 1 hour with periodic mixing. Typically, 5-10 x 10 ⁹ cells were lysed in 50-100 ml of detergent solution. The lysate was centrifuged at 15,000 × g for 30 minutes at 4 ° C., then the supernatant portion was passed through a 0.2 μ filter unit (Nalgene) to purify.
[139] HLA-A antigen purification was performed using an affinity column made of mAb-conjugated Sepharose beads. To generate antibodies, cells were grown in RPMI containing 10% FBS in large tissue culture flasks (Corning 25160-225). Antibodies were purified from clarified tissue culture media using affinity chromatography on Protein-A-Sepharose (Sigma) after ammonium sulfate fractionation. In summary, saturated ammonium sulfate was added to the tissue culture supernatant with stirring slowly at 4 ° C. until 45% (volume vs. volume) overnight to precipitate immunoglobulins. The precipitated protein was collected by centrifugation at 10,000 x g for 30 minutes. The precipitate was then dissolved in a minimal amount of PBS and transferred to a dialysis tube (Spectro / Por 2, Mol. Wt. Cutoff 12,000-14,000, Spectum Medical Ind.). Dialysis buffer was replaced 4-6 times at 4 ° C. for 24-48 hours and dialyzed against PBS (more than 20 times the volume of protein solution). The dialyzed protein solution was clarified by centrifugation (10,000 × g for 30 min) and the pH of the solution was adjusted to pH 8.0 with 1N NaOH. Protein-A-Sepharose (Sigma) was hydrated according to the manufacturer's instructions and a Protein-A-Sepharose column was prepared. Columns of 10 ml fill volume typically bind 50-100 mg of mouse IgG.
[140] Protein samples were packed onto protein-A-Sepharose columns by gravity using a peristaltic pump when the fill volume was large or by gravity when the volume was small (<100 ml). The column was washed with a large amount of PBS and the eluate was monitored at A280 with a spectrophotometer until reaching baseline. Bound antibody was eluted with 0.1 M citric acid under moderate pH (adjusted to moderate pH with 1N NaOH). PH 6.5 was used for mouse IgG-1, pH 4.5 was used for IgG2a and pH 3 was used for IgG2b and IgG3. The eluate was neutralized with 2M Tris base. Fractions containing antibody (monitored by A280) were collected, dialyzed against PBS, and further concentrated using an Amicon Stirred Cell system (Amicon Model 8050 with YM30 membrane). Anti-A2 mAb, BB7.2, was useful for affinity purification.
[141] HLA-A antigen was purified using an affinity column made of mAb-conjugated Sepharose beads. An affinity column was prepared by incubating Protein-A-Sepharose Beads (Sigma) with affinity-purified mAB as described above. 5-10 mg of mAB per ml of beads is the preferred ratio. mAB bound beads were washed with borate buffer (borate buffer: 100 mM sodium tetraborate, 154 mM NaCl, pH 8.2) until the wash showed A280 at baseline. Dimethyl pilimimidate (20 mM) in 200 mM triethanolamine was added to covalently crosslink the bound mAB to Protein-A-Sepharose . Schneider, et al. , J. Biol. Chem. 257: 10766 (1982). After incubation for 45 minutes at room temperature on the rotor, excess crosslinking reagent was removed by washing the beads twice with 10-20 ml (pH 8.2) of 20 mM ethanolamine. Between each, the slurry was placed on the rotor at room temperature for 5 minutes. The beads were washed with borate buffer and washed with PBS + 0.02% sodium azide.
[142] The cell lysate (5-10 × 10 ⁹ cell equivalents) can then be passed slowly through a 5-10 ml affinity column (flow rate of 0.1-0.25 ml per minute) to allow antigen to bind to immobilized antibody. After passing the lysate through the column, the column was subjected to 20 column volumes of detergent stock solution + 0.1% sodium dodecyl sulfate, 20 column volumes of 0.5 M NaCl, 20 mM Tris (pH 8.0), and 20 mM Tris (pH 8.0) It was washed sequentially with 10 column amounts of. HLA-A antigen bound to mAb was eluted with basic buffer solution (50 mM dimethylamine in water). As an alternative, the bound antigen was eluted using an acid solution such as 0.15 to 0.25 M acetic acid. Aliquots (1/50) of the eluate were separated and protein quantified using colorimetric coloration (BCA analysis, Pierce) or SDS-PAGE, or both. SDS-PAGE analysis was performed as described in Laemmli, UK, Nature 227: 680 (1970) using known amounts of bovine serum albumin (Sigma) as protein standards. Allele specific antibodies were used to purify specific MHC molecules. For HLA-A2, mAb BB7.2 was used.
[143] A detailed description of the protocol used to determine the binding of peptides to type I HLA molecules has been published. Sette, et al ., Mol. Immunol. 31: 813, 1994; Sidney, et al. , in Current Protocols in Immunology , Margulies, Ed., John Wiley & Sons, New York, Section 18.3, 1998]. In summary, purified MHC molecules (5-500 nM) were treated with 0.05% Nonidet P-40 (NP40) (or H-) for 48 hours with various unlabeled peptide inhibitors and 1-10 nM ¹²⁵ I-radiated probe peptides. Incubated in the presence of a protease inhibitor cocktail in PBS containing 20% w / v digtoninin) for the 2 IA assay. Final concentrations of protease inhibitors (CalBioChem, La Jolla, CA) were 1 mM PMSF, 1.3 nM 1.10 phenanthroline, 73 μM pepstatin A, 8 mM EDTA, 6 mM N-ethylmaleimide, and 200 μM N alpha-p -Tosyl-L-lysine chloromethyl ketone (TLCK). All assays were performed at pH 7.0.
[144] After incubation, the MHC-peptide complex was eluted at 1.2 mls / min with 7.8 mm × 15 cm TSK200 column (TosoHaas 16215, Montgomeryville, Pa.) With PBS (pH 6.5) containing 0.5% NP40 and 0.1% NaN ₃ . Isolation from the free peptide by gel filtration. Eluate from the TSK column was passed through a Beckman 170 radioisotope detector, plotted radioactivity, integrated using a Hewlett-Packard 3396A integrator, and the fraction of bound peptide was measured.
[145] Radiolabeled peptides were iodinated using the chloramine-T method. Specific radiolabeled probe peptides were used in each assay. Typically, in preliminary experiments, each MHC preparation was titrated in the presence of a fixed amount of radiolabeled peptide to determine the concentration of HLA molecules required to bind 10-20% of the total radioactivity. All subsequent inhibition and direct binding assays were performed using these HLA concentrations.
[146] Since under these conditions [label] <[HLA] and IC ₅₀ ≧ [HLA], the measured IC ₅₀ value is a reasonable estimate of the actual K _D value. Peptide inhibitors are typically tested at concentrations ranging from 120 μg / ml to 1.2 ng / ml and tested in two to four completely independent experiments. To compare the data obtained in different experiments, the IC ₅₀ of the inhibitory control, i.e., the reference peptide included in each binding assay, was used to determine the IC of each tested peptide (typically unlabeled form of radiolabeled probe peptide). Calculate the relative number of bonds for each peptide by dividing by ₅₀ . For comparison of database purposes and cross experiments, edit the relative binding values. Subsequently these values can be converted to normalized IC ₅₀ nM values by dividing the standard actual IC ₅₀ of the reference peptide by the relative binding of the desired peptide. This data editing method was most accurate and proved to be consistent when comparing peptides tested using different quotas of MHC tested or purified on different days. For example, the standard reference peptide (or positive control) for the HLA-A2.1 binding assay described herein is a peptide with a sequence of FLPSDYFPSV, which has an average practical IC ₅₀ value of 5 nM in several repeated binding assays. This was. These standard values were used to normalize reported IC ₅₀ values for the HLA-A2.1 binding described herein. Thus, the relative binding value of the test HLA-A2.1 motif-bearing peptide is given by the IC ₅₀ normalized by dividing the standard reference IC ₅₀ value, ie 5 nM by the binding value of the test HLA-A2.1 motif-bearing peptide. Can be switched.
[147] Example 5: Sequencing and Binding Analysis
[148] Using the assay described in Example 3, the relative binding values for each peptide were calculated by dividing the IC ₅₀ of the inhibitory positive control by the IC ₅₀ of each tested peptide. Subsequently these values can be converted back to IC ₅₀ nM values by dividing the IC ₅₀ nM of the inhibitory positive control by the relative binding of the desired peptide. This data editing method was proven to be accurate and consistent when comparing peptides tested using different quotas of MHC tested or purified on different days. In addition, standardized relative binding values can be used to calculate the geometric mean, or average relative binding value (ARB) for all peptides with a particular characteristic. See Ruppert, J., et al ., “ Prominent Role of Secondary Anchor Residues in Peptide Binding to HLA-A2.1 Molecules, " Cell 74: 929-937 (1993); Sidney, J., et al ., "Definition of an HLA-A3-Like Supermotif Demonstrates the Overlapping Peptide Binding Repertoires of Common HLA Molecules," Hum Immunol . 45: 79-93 (1996); Sidney, J., et al ., "Specificity and Degeneracy in Peptide Binding to HLA-B7-Like Class I Molecules," J. Immunol . 157: 3480-3490 (1996); Kondo, A., et al ., "Prominent Roles of Secondary Anchor Residues in Peptide Binding to HLA-A24 Human Class I Molecules," J. Immunol . 155: 4307-4312 (1995); Kondo, A., et al ., Two Distinct HLA-A * 0101-Specific Submotifs Illustrate Alternative Peptide Binding Modes, " Immunogenetics 45: 249-258 (1997); Gulukota, K., et al ., Two Complementary Methods for Predicting Peptides Binding Major Histocompatibility Complex Molecules, " J. Mol. Biol . 267: 1258-1267 (1997); Southwood, S., et al ., "Several Common HLA-DR Types Share Largely Overlapping Peptide Binding Repertoires," J. Immunol 160: 3363-3373 (1998).
[149] Based on ARB, a map of secondary interactions affecting peptide binding to HLA-A2 supertype molecules was inferred as described previously. Ruppert, J. et al ., "Prominent Role of Secondary Anchor Residues in Peptide Binding to HLA-A2.1 Molecules, " Cell 74: 929-937 (1993); Sidney, J., et al ., "Definition of an HLA-A3-Like Supermotif Demonstrates the Overlapping Peptide Binding Repertoires of Common HLA Molecules," Hum Immunol . 45: 79-93 (1996); Sidney, J., et al ., "Specificity and Degeneracy in Peptide Binding to HLA-B7-Like Class I Molecules," J. Immunol . 157: 3480-3490 (1996); Kondo, A., et al ., "Prominent Roles of Secondary Anchor Residues in Peptide Binding to HLA-A24 Human Class I Molecules," J. Immunol . 155: 4307-4312 (1995); Kondo, A., et al ., "Two Distinct HLA-A * 0101-Specific Submotifs Illustrate Alternative Peptide Binding Modes," Immunogenetics 45: 249-258 (1997); Gulukota, K., et al ., "Two Complementary Methods for Predicting Peptides Binding Major Histocompatibility Complex Molecules," J. Mol. Biol . 267: 1258-1267 (1997). Essentially, all peptides of a given size (8, 9, 10 or 11 amino acids) with one or more commonly used major anchor residues were selected for analysis. The binding capacity of peptides of each size group was analyzed by measuring ARB values for peptides containing specific amino acids at specific positions. To determine specificity at key anchor positions, ARB values were standardized against the ARB of the peptides with residues that bound with the best binding. For secondary anchor determinations, ARB values were normalized against ARB of the entire set of peptides considered. That is, for example, ARB values were measured for all 9-mer peptides containing A at position 1 or F at position 7 and the like. Because of the rare presence of certain amino acids, in some assays residues were classified according to their individual chemical similarities as described previously (Ruppert, J. et al ., Supra ; Sidney, J., et al ., Supra ; Sidney, J., et al ., Supra ; Kondo, A., et al ., Supra ; Kondo, A., et al ., Supra ; . Gulukota, K., et al, supra; Southwood, S., et al ., Supra ].
[150] Frequency of HLA-A2-Supertype Molecules
[151] To select a panel of A2-supertype molecules that represent the most common allelic type in a major ethnic group, d. D. Mann and M. Unpublished population typing data from M. Fernandez-Vina was used. These data were consistent with published data, see Sudo, T., et al ., "DNA Typing for HLA Class I Alleles: I. Subsets of HLA-A2 and of -A28," Hum. Immunol . 33: 163-173 (1992); Ellis, JM, et al ., "Frequencies of HLA-A2 alleles in Five US Population Groups," Hum. Immunol . 61: 334-340 (2000); Krausa, P., et al ., "Genetic Polymorphism Within HLA-A * 02: Significant Allelic Variation Revealed in Different Populations," Tissue Antigens 45: 233-231 (1995) and Imanishi, T., et al ., "Allele and Haplotype Frequencies for HLA and Complement Loci in Various Ethnic Groups "Tsuji, K., et al ., (eds): HLA 1991, Proceedings of the Eleventh International Histo-Compatibility Workshop and Conference, Vol. 1., Oxford University Press , Oxford, pp. 1065-1220 (1992)]. For the four major ethnic groups considered, it was clear that the seven HLA alleles represented almost the majority of the A2 supertype allele. These groups include A * 0201, A * 0202, A * 0203, A * 0205, A * 0206, A * 0207, and A * 6802. Each of these alleles is present in at least 2% of the overall population and is also present at a frequency of at least 5% in one or more major races. Other alleles appear only in a minority of less than 1.3% in any major ethnic group. In addition, none of the few alleles are present at frequencies greater than 1% in the overall population. Based on this observation, A * 0201, A * 0202, A * 0203, A * 0205, A * 0206, A * 0207, and A * 6802 define peptide binding specificity and cross-reactivity in A2-supertype. Is selected for the study.
[152] Major Anchor Locations of A2 Supertype Molecules
[153] Previous studies have shown primarily overlapping peptide binding specificities for a set of type I molecules named A2-supertypes. Herein, the major peptide binding specificities of A-supertype molecules were studied in more detail. Some of these results have been previously published and are presented here for reference only. Rupert, J., et al., Supra and Sidney, J., et al., “The HLA-A * 0207 Peptide Binding Repertoire is Limited to a Subset of the A * 0201 Repetoire, " Hum. Immunol. , 58: 12-20 (1997).
[154] In a first series of studies, non-conservative lysine (K) substitutions were introduced at all positions of the two peptides mentioned above as binding to multiple A2-supertype molecules: 1) HCV NS3 590 9-mer peptide (SEQ ID NO: YLVAYQATV), and 2) HBV core 18 F ₆ > Y 10-mer homolog peptide (SEQ ID NO: FLPSDYFPSV). These peptides were tested for their ability to bind A * 0201, A * 0202, A * 0203, A * 0205, A * 0206, A * 0207 and A * 6802. In Tables 4a and 4b, the binding capacity is expressed as a ratio to the parent peptide. Peptides having a binding capacity of less than 10 times the best binder are considered to be preferred; It is contemplated that relative binding capacity is 10 to 100 times less than the best binder. A dash ("-") indicates a relative bond of less than 0.01. In the case of the HCV NS3 590 peptide (Table 4a), K substitution at position 2 and the C-terminus reduced binding to each HLA molecule by at least 100 fold. A decrease in binding of more than 100-fold was seen at A * 6802 when K was substituted at positions 1 and 5. The decrease in binding capacity in the range of 10 to 100 fold was seen when the substitution took place at several different positions, in particular positions 3 and 7. When studying the 10-mer HBV core 18 F ₆ > Y ligand (Table 4b), a reduction in binding capacity of at least 100-fold appeared again when the peptide was substituted at position 2 and the C-terminus. A significant decrease in binding was observed after substitution at position 7.
[155] Taken together, these data suggest that the A2-supertype molecule binds to both 9- and 10-mer peptide ligands via anchor residues at positions 2 and C-terminus. The presence of additional primary or secondary anchors to the middle of the peptide was evidenced by the fact that binding to both 9- and 10-mer peptides is typically reduced by substitution at position 7.
[156]
[157]
[158]
[159] Specificity of Position 2 and C-terminal Anchor Residues
[160] Based on these results, the ligand specificity of the A2-supertype molecule at positions 2 and C-terminus additionally the HCV NS3 590 and HBV core 18 F ₆ > Y single substituted analogs, as well as the single substituted homologs of the poly-alanine peptide ( Peptide 953.01; sequence ALAKAAAAV). In these assays, amino acids preferred as anchor residues are defined as those that bind with a binding capacity within 10 times the optimal residue. Amino acids with a relative binding capacity of 0.01 to 0.1 are defined as tolerated, and binding with a binding capacity of less than 0.01 was considered to be unacceptable. In the table, dashes ("-") indicate a relative bond of less than 0.01. Binding capacity is expressed as the ratio for related homologues with the highest binding affinity for each individual molecule.
[161] Small aliphatic and hydrophobic residues at position 2 have been found to be generally tolerated, and other residues, such as large polar, aromatic, and charged residues, are typically rarely tolerated (Tables 5a, 5b, and 5c). L, I, V and M were preferred as anchor residues in most (> 80%) (Table 5d). Allele / peptide combinations in Table 5d represent the number of cases where a given residue is bound by relative binding in the range of 1 to 0.1 (preferably) or in the range of 0.1 to 0.001 (typical). A, T, Q and S were less often preferred as anchor residues, but were preferred or idiomatic in more than 80% of the cases investigated. None of the other amino acids was desirable in any case, only rarely tolerated.
[162]
[163]
[164]
[165]
[166] At the C-terminus, V is found to be the optimal residue in all three parent peptides in A * 0201, A * 0206, and A * 6802, and in 2 of 3 cases in A * 0203 and A * 0205. (Tables 6a, 6b and 6c). Overall, V or L was the optimal C-terminal residue for each molecule, regardless of the peptide tested. The allele / peptide combinations in Table 6d represent the number of cases where a given residue is bound by relative binding in the range of 1 to 0.1 (preferably) or 0.1 to 0.01 (volume). Aliphatic / hydrophobic amino acids V, L, and I are preferred as anchor residues in at least 66.7% of the MHC-peptides. M, A, and T were tolerated to about 50% of this fold. Other residues examined were not allowed at all or were rarely tolerated.
[167] Reassessment of Peptide Binding Specificity of A * 0201
[168] The microspecificity of A * 0201 binding was studied in more detail using a database of 4000 peptides with 8-11 residues in length. It was found that at least 30% of the peptides having L or M in position 2 bind A * 0201 with affinity of at least 500 nM (FIG. 1A). 5-15% of peptides having aliphatic residues I, V, A, T, and Q bound with an IC ₅₀ of at least 500 nM. None of the other residues including aromatic (F, W, and Y), charged (R, H, K, D, and E), polar (S and N), and small (C, G, and P) residues. It did not bind with an IC ₅₀ greater than nM.
[169] Consistent with the single substitution analysis, V was found to be the optimal A * 0201 C-terminal anchor residue (FIG. 1B). Overall, 31.9% of the peptides with V at the C-terminus were A * 0201 binders. I, L, S, C, M, T and A were also tolerated, with 7.1 to 28.6% of peptide bonds having an IC _{50 of} at least 500 nM.
[170] The correlation between peptide length (8-11 residues) and binding capacity was then analyzed. It was found that 27.6% of the 9-mer peptides bind with an IC ₅₀ of 500 nM or less, which is in exact agreement with previous estimates (Rupert, J., et al., Supra ) (Table 7a). ARB values were normalized to a set of peptides of optimal size and presented for reference.
[171] Although somewhat weak, long chain peptides are also capable of binding; 17.8% of 10-mers, and 14.5% of 11-mers had affinity of at least 500 nM. Finally, the 8-mer peptide only rarely binds to A * 0201, with 3.5% of the peptides having a binding capacity of at least 500 nM.
[172] The A * 0201 peptide binding database was further analyzed to estimate the stringency of the A * 0201 motif. As expected, the peptide with the desired moiety at each anchor position binds most frequently (48.7%) and the average relative binding capacity was higher than other peptides in the library (Table 7b).
[173]
[174]
[175]
[176]
[177]
[178]
[179] Peptides with one preferred residue and one commonly used residue were also relatively frequently bound in the range of 17.6% to 28.4%. Finally, peptides with one or more untolerable residues, or residues that are tolerant of all major acker positions, only rarely, although bound, bound with a binding frequency ranging from 0 to 7.1%. No significant difference was found in terms of primary anchor preference as a function of ligand size.
[180] To confirm the secondary anchoring effect, the A * 0201 binding capacity of the peptides in each size group was further analyzed by measuring the ARB values of the peptides containing specific amino acids at specific locations according to size. For 8-11-mer sequences, the ARB values obtained by the corresponding residue / position pairs are shown in Tables 8a-8d. All peptides in Tables 8A-8D had at least one preferred residue and one tolerable residue at the major anchor position. At secondary anchor positions, values corresponding to binding capacity increased by three or more times are shown in enlarged bold. Negative effects associated with a threefold reduction in binding affinity are identified in underlined, italic type. In addition, residues determined as preferred or tolerated anchors are shown in bold. The ARB value of the anchor position was inferred from the analysis described in FIG. 1. In order to use the values presented in the table as coefficients for the prediction algorithm, the non-motif peptide is removed by filtration, setting the value for the unacceptable anchor residue to 0.001 corresponding to a 1000-fold reduction in binding capacity.
[181] In Tables 8a, 8b, 8c, and 8d, the assays of 93 panels of 8-mer peptides, 1389 panels of 9-mer peptides, 953 panels of 10-mers, and 95 panels of 11-mers were shown for various viruses, bacteria or pathogens, respectively. It is based on the native sequence to origin. The ARB values presented were calculated as described, for example, in Sidney et al., Human Immunology 62: 1200 (2001) and Sidney et al., J. Immunology 157: 3480 (1996). For 9- and 10-mer peptides, the ARB values for each residue considered separately were deduced. For the 8- and 11-mer peptides (Tables 8a and 8b, respectively), the ARB values are according to the classification of chemically similar residues (Ruppert et al., Cell 74: 929 (1993)). The average geometric binding capacities of the 8-, 9-, 10- and 11-mer panels were 14420 nM, 1581 nM, 3155 nM, and 3793 nM, respectively.
[182] Summary maps are shown in FIGS. 2A-2D. At most locations, some secondary effects can be found. Most of the negative effects (55%) were associated with the presence of acidic (D and E) or basic (R, H and K) residues. Proline (P) and large polar residues (Q and N) were also often disruptive. While each specific size was associated with a specific preference, in most cases (79%) preferred residues were aromatic (F, W or Y) or hydrophobic (L, I, V, or M). Most peptide lengths showed preference for F, Y and M at position 3. Similarly, all peptide sizes shared preference for aromatic or hydrophobic residues at the C-2 position.
[183]
[184]
[185]
[186]
[187] Several different affinity patterns were observed for peptides of a given size. For example, the 8-mer peptide did not have any preference at position 1 or position 3 for the hydrophobic or aromatic residues favored by the 9-, 10- and 11-mer peptides. 11-mer peptides were unique in that they had affinity for G at multiple sites through the middle of the peptide.
[188] Major Anchor Specificity of Other A2-Supertype Molecules
[189] In the next set of analyzes, the major anchor specificities of the four A2-supertype alleles, A * 0202, A * 0203, A * 0206, and A * 6802, which were most prevalent after A * 0201, were evaluated. Peptides in the A2-supertype binding database often reflect selection using A * 0201-based bias, eg, only A * 0201 binding peptides, or selection of peptides with high scores in the A * 0201 algorithm. . As a result, in most cases peptide binding data for non-A * 0201 molecules can be used only for peptides with supertypes of preferred and tolerable residues. Despite this limitation, a database of about 400 peptides can be used for the study. Although the specificity of A * 0207 has already been published [Sidney, J., et. al., supra ], databases of sufficient size were not available for analysis of A * 0205 and A * 0207.
[190] Analysis of position 2 specificity is summarized in FIGS. 3A-D. In general, V, T, A, I, and M were tolerated for each molecule. Allele specific preferences were also observed. The most preferred residue for A * 0202 Q was Q. Other residues (L, I, V, A, T and M) were tolerated, approximately equivalent, and ARB ranged from 0.08 to 0.30. In contrast, A * 0203 had preference for L, M and Q. Residues V, A, I and T were associated with lower overall binding affinity. A third pattern was observed at A * 0206, where Q, V, I, A, and T were all well tolerated, while the ARB values were 0.47 to 1.0, while L and M were less well tolerated. Finally, for A * 6802 V and T were optimal residues and ARB> 0.45. A is also preferred, but ARB is lower (0.13). Significant decreases in binding were observed at I and M, which had ARBs between 0.050 and 0.020. L and Q were not tolerated with ARB <0.010. At the C-terminus, I, V, L, A, M and T were tolerated by all A2-supertype molecules tested, with ARB> 0.060 (FIGS. 4A-D). I and V are the two residues most preferred by each allele; V was the best residue for A * 0203, A * 0206, and A * 6802. L was usually the next most preferred residue. T, A, and M are typically associated with lower ARB values.
[191] In conclusion, the position 2 and C-terminal anchor residues favored or tolerated by A * 0201 were also well tolerated by other A2 supertype molecules. While each allele had a somewhat unique preference pattern at position 2, the preference pattern exhibited by each allele at the C-terminus was very similar.
[192] Secondary Effects on Peptide Binding to A2-Supertype Molecules
[193] The same library of peptide ligands is analyzed to determine ligand size preferences of A * 0202, A * 0203, A * 0206, and A * 6802. For each allele, ARB values were normalized to a set of peptides of optimal size. The inventors have found that for each molecule, 9 to 11-mer peptides are well tolerated and have an ARB> 0.36 (Tables 9 a to d). For A * 0203, A * 0206, and A * 6802, the 9-mer peptide was optimal, while the 10-mer was optimal for A * 0202. For all alleles, the 8-mer peptide was much less well tolerated, with ARB <0.11 in each case.
[194]
[195]
[196]
[197]
[198] Next, the effect of secondary anchor residues on the ability of peptides to bind A * 0202, A * 0203, A * 0206, and A * 6802 was investigated. The number of uniquely available peptides allowed the analysis of 9- and 10-mers. ARB values for the 9- and 10-mer peptides as a function of the presence of certain residues at specific positions are shown in Tables 10-13, and the summary maps of FIGS. As noted above, the positive and negative effects are defined to be associated with an increase or decrease in binding affinity by three or more times, respectively.
[199] In Tables 10a and 10b, a panel of 268 9-mer peptides and 120 panels of 10-mer peptides were tested for binding to the A * 0202 allele, respectively. In Tables 11a and 11b, a panel of 272 9-mer peptides and 122 panels of 10-mer peptides were tested for binding to the A * 0202 allele, respectively. In Tables 12a and 12b, a panel of 268 9-mer peptides and 120 panels of 10-mer peptides were tested for binding to the A * 0206 allele, respectively. In Tables 13a and 13b, a panel of 268 9-mer peptides and 120 panels of 10-mer peptides were tested for binding to the A * 6802 allele, respectively. All peptides are based on native sequences from various viral, bacterial or pathogen sources and have at least one preferred residue and one tolerable residue at the major anchor position. ARB values are according to the classification of chemically similar residues (Ruppert et al., Cell 74: 929 (1993)). At secondary anchor positions, values corresponding to binding capacity increased by three or more times are shown in enlarged bold. Negative effects associated with a threefold reduction in binding affinity are shown in underlined, italic type. In addition, residues determined as preferred or tolerated anchors are shown in bold. In order to use the values presented in the table as coefficients for the prediction algorithm, the non-motif peptide is removed by filtration, setting the value for the unacceptable anchor residue to 0.001 corresponding to a 1000-fold reduction in binding capacity. In Tables 10a, 10b, 11a, 12a, 12b, 13a, and 13b, the average geometrical binding capacity of each panel was 401nM, 342nM, 85nM, 95nM, 387nM, 643nM, 838nM, and 1055nM, respectively.
[200] In general, adverse effects were often (35%) associated with charged residues (D, E, R, H, or K). An additional 35% of the adverse effects may be due to G or P. The positive effect was relatively evenly due to basic (R, H, K), acid (D, E), hydrophobic (F, W, Y, L, I, V, M) or small (A, P) residues. .
[201] Although each molecule has a unique preference and half sensitivity pattern, a common propensity could be observed for 10-mer peptides. For example, for all molecules Q and N are preferred at position 1 and R, H, and K are preferred at position 8. D, E, and G were consistently harmful at position 3 for the 10-mer peptide. Consensus preference and half sensitivity were not observed for 9-mer peptides.
[202]
[203]
[204]
[205]
[206]
[207]
[208]
[209]
[210] In summary, the data in this section describe detailed motifs for 9- and 10-mer peptides that bind to A * 0202, A * 0203, A * 0206, and A * 6802. Each motif is characterized by specific features associated with good or bad binding peptides.
[211] Consensus A2-Super Motif
[212] The motifs described above for the A2 supertype are very similar and mainly overlap. In this respect, consensus motifs can be identified which introduce features shared jointly by molecular-specific motifs (FIG. 9). Consensus motifs clarify the presence of hydrophobic and aliphatic residues at position 2 of the peptide ligand. V, L and M are preferred in this position, while T, Q, A, and I are all tolerated. For each A2-supertype molecule, V is the most preferred moiety based on each residue's affinity rating. Consensus motifs at the C-terminus clarify the presence of hydrophobic and aliphatic residues L, I, V, M, A and T. While V is the most common optimal residue, L and I are also preferred and are generally considered to be the next most optimal residue. M, A, and T are considered to be common residues.
[213] Secondary anchor maps for A * 0201, A * 0202, A * 0203, A * 0206, and A * 6802 were used to deduce supertype consensus secondary anchor motifs for 9- and 10-mer peptides ( 9). Without detriment to any molecule, residues considered to be preferred for at least three A2-supertype molecules were considered to be preferred as supertype consensus motifs. In contrast, residues identified as harmful to three or more molecules have been designated as harmful in consensus motifs. Consensus motifs overlap significantly with detail A * 0201 motifs, include preferences for aromatic residues at positions 1 and / or 3, and share half sensitivity to charged residues at position 3.
[214] Correlation Between A * 0201 Binding Affinity and A2-Supertype Cross-Reactivity
[215] Since A * 0201 predominates in four major races compared to other A2 supertype alleles, it was important to measure how satisfactorily the A * 0201 binder binds to other supertype molecules. Peptides that bind A * 0201 with good affinity (IC ₅₀ <500 nM) were found to bind to other A2-supertype molecules poorly (Table 14a). 36.1-73.6% of A * 0201 binding peptides bound to other A2-supertype molecules. Interesting results were obtained when analyzing A2-supertype degeneracy as a function of A * 0201 affinity. 72.8% of peptides that bind A * 0201 with an IC ₅₀ <500 nM bound to at least three A2-supertype molecules (Table 14b). In general, the higher the binding affinity of a peptide for A * 0201, the higher the likelihood that the peptide will bind to three or more supertype molecules. At least 96% of peptides that bind A * 0201 with affinity of at least 20 nM also bound to at least three A2-supertype molecules. In contrast, A2-supertype peptides that do not bind A * 0201 with affinity of 500 nM or more bind very rarely (10%) with three or more A2 supertype molecules and never with four or more molecules.
[216] In summary, the analysis of cross-reactivity to A * 0201 and other A2-supertype molecules confirmed that these families of HLA molecules recognize similar structural features of their peptide ligands. It was also found that A * 0201 binding affinity correlates with the propensity to bind multiple A2-supertype alleles.
[217]
[218]
[219] analysis
[220] This analysis allows for the characterization of peptides that bind to HLA-A * 0201 and other A2-supertype molecules in detail. A2-supertype molecules share not only overlapping peptide binding specificities but also significantly overlapping peptide binding repertoires. Specific characteristics of peptide ligands associated with degenerate A2-supertype binding capacity have been identified, which logically explained the supertype relationship.
[221] In previous studies, peptide binding specificity of A * 0201 was analyzed and detailed motifs were constructed that included identification of secondary anchor characteristics. In this analysis performed using a 10-fold larger database, the inventors of the present application confirmed this data and extended the analysis to include 8- and 11-mer peptides. Taken together, the specificity of A * 0201 for 8- and 11-mer peptides was very similar to that of 9- and 10-mers. For example, regardless of peptide size, most of the negative effects on binding capacity were associated with the presence of charged residues at secondary anchor positions, and most of the positive effects were associated with the presence of hydrophobic residues. Defining detailed motifs for 8- and 11-mer peptides allowed epitopes to be more fully identified. The identification of A * 0201 binders has been greatly facilitated by using algorithms based on ARB values. In this analysis, algorithm coefficients can be fine-grained by using a substantially larger database than previously used. Because newer coefficients are based on significantly larger data sets, they are statistically more accurate and allow for more efficient and accurate prediction of epitopes. Indeed, recent analysis has shown that the modified A * 0201 9-mer polynomial algorithm based on larger data sets is more accurate than both older algorithms based on smaller data sets, and neural network prediction methodologies. Increasing the accuracy of epitope predictions . Rupert, J., et al., Supra; Sidney, J., et al ., Supra; Kondo, A., et al., Supra ; Gulukota, K., et al., Supra; Parker, KC, et al ., "Sequence Motifs Important for Peptide Binding to the Human MHC Class I Molecule, HLA-A2," J. Immunol . 149: 3580-3587 (1992) and Milik, M., et al. In addition to "Application of an Artificial Neural Network to Predict Specific Class I MHC Binding Peptide Sequences," Nature (Biotech ) 16: 753-756 (1998), detailed peptide binding motifs that define both primary and secondary anchor positions. , We can reasonably devise an optimized regard. For example, native sequences having primary and / or secondary position sub-optimal residues can be identified. Sub-optimal residues can be replaced with optimal anchors, resulting in epitopes with increased binding affinity (Sidney, J., et al., Supra; Pogue, RR, et al ., "Amino-Terminal Alteration of the HLA-A * 0201-Restricted Human Immunodeficiency Virus Pol Peptide Increases Complex Stability and in Vitro Immunogenicity," Proc. Nat'l. Acad. Sci ., USA, 92: 8166-8170 (1995) and Bakker, AB, et al ., "Analogues of CTL epitopes With Improved MHC Class-I Binding Capacity Elicit Anti-Melanoma CTL Recognizing the Wide-Type Epitope," Int. J. Cancer , 70: 302-309 (1997). After this type of modification, wild-type peptides that are inducible or poorly immunogenic may be highly immunogenic [Pogue, RR, et al., Supra ; Bakker, AB, et al., Supra ; Parkhurst, MR, "Improved Induction of Melanoma-Reactive CTL With Peptides From the Melanoma Antigen gp100 Modified at HLA-A * 0201-Binding Peptides," J. Immunol . 157: 2539-2548 (1996); Rosenberg, SA, et al ., "Immunologic and Therapeutic Evaluation of a Synthetic Peptide Vaccine for the Treatment of Patients With Metastatic Melanoma," Nature (Med) 4: 321-327 (1998); Sarobe, P., et al ., "Enhanced in vitro Potency and in vivo Immunogenicity of a CTL Epitope From Hepatitis C Virus Core Protein Following Amino Acid Replacement at Secondary HLA-A2.1binding positions," J. Clin. Invest . 102: 1239-1248 (1998) and Ahlers, JD, et al ., "Enhanced Immunogenicity of HIV-1 Vaccine Construct by Modification of the Native Peptide Sequence," Proc. Nat'l Acad. Sci ., USA, 94: 10856-10861 (1997). CTLs induced by such homolog peptides have been found to be able to recognize target cells expressing wild-type antigen sequences in most cases. This phenomenon appears to reflect less stringent epitope binding requirements in target cell recognition than is required for stimulation of natural T-cells leading to differentiation into effectors. Cho, BK, et al ., “ Functional Differences Between Memory and Naive CD8 T Cells, " Proc. Nat'l. Acad. Sci . USA 96: 2976-2981 (1999); Sykulev, Y., et al ., "Evidence That A Single Peptide-MHC Complex On A Target Cell Can Elicit Acytolytic T Cell Response," Immunity 4: 565-571 (1996)]. Thus, the detailed motifs described herein will facilitate the design of genetically engineered epitopes with increased binding capacity and / or immunogenicity, as well as the identification of native CTL epitopes.
[222] Peptide binding specificity for other A2-supertype molecules was studied using single substituted homologue peptides and peptide libraries. Earlier reports [del guercio, MF, et al ., "Binding of a Peptide Antigen to Multiple HLA Alleles Allows Definition of an A2-Like Supertype," J. Immunol . 154: 685-693 (1995) and (Sidney, J., et al ., "Practical, Biochemical and Evolutionary Implications of the Discovery of HLA Class I Supermotifs," Immunol Today 17: 261-266 (1996)); Consistent with the report filed for NIH-NIAID contract NO1-AI-45241, the inventors have found that the primary anchor motifs of A2-supertype molecules are significantly similar. By using peptide libraries, it is possible to characterize the fine properties of the secondary anchor preference and half sensitivity of each molecule. It has been found that each A2-supertype molecule can have unique specificities, and supermotifs based on consensus patterns can be identified. Since the supermotifs characterize the peptide ligands shared between A2-supertype molecules, it is expected that efficient identification of highly cross-reactive peptides and suitable methods for anchor anchoring could be suggested, and peptide ligands. You can adjust the supertype degeneracy of. Another result of this analysis is the inference of the coefficients that can be used in the algorithm to predict peptide binding to A * 0202, A * 0203, A * 0206, and A * 6802.
[223] Since HLA A * 0201 is by far the most prevalent A2-supertype allele in the overall population and major ethnic groups, the peptide screening strategy used was first focused on the identification of A * 0201 binders. It is determined that more than 70% of the peptides that bind A * 0201 also bind to two or more additional A2-supertype molecules, and that the propensity to bind other A2-supertype alleles correlates with A * 0201 binding affinity. It became.
[224] In conclusion, the data described herein provide formal evidence of the shared peptide binding specificity of the HLA-A molecular group designated A2-supertype. Not only do these molecules recognize similar features at the primary and secondary anchor positions of their peptide ligands, they also share primarily overlapping peptide binding repertoires. Evidence that these molecules share a predominantly overlapping repertoire suggests significant implications for designing potential vaccine constructs. Indeed, the notion that A2-supertype cross-reactivity at the level of peptide binding is immunologically related has been reported through numerous studies in infectious diseases [Khanna R., et al ., “Identification of Cytotoxic T-Cell Epitopes”. Within Epstein-Barr Virus (EBV) Oncogene Latent Membrane Protein 1 (LMP1): Evidence for HLA A2 Supertype-Restricted Immune Recognition of EBV-Infected Cells by LMP1-Specific Cytotoxic T lymphocytes, " Eur J Immunol , 28: 451-458 ( 1998); Bertoletti, A., et al ., "Molecular Features of the Hepatitis B Virus Nucleocapsid T-Cell Epitope 18-27: Interaction With HLA An T-Cell Receptor," Hepatology 26: 1027-1034 (1997); Livingston, BD, et al ., "Immunization With the HBV Core 18-27 Epitope Elicits CTL Responses in Humans Expressing Different HLA-A2 Supertype Molecules," Hum Immunol 60: 1013-1017, (1999); Bertoni, R., et al ., "Human Histocompatibility Leukocyte Antigen-Binding Supermotifs Predict Broadly Cross-Reactive Cytotoxic T Lymphocyte Responses in Patients With Acute Hepatitis," J Clin Invest 100: 503-513 (1997); and Doolan, DL, et al ., "Degenerate Cytotoxic T-Cell Epitopes from P. falciparum Restricted by Multiple HLA-A and HLA-B Supertype Alleles," Immunity 7: 97-112 (1997)] and cancer [Ref. Fleischhauer, K., et al. , "Multiple HLA-A Alleles Can Present an Immunodominant Peptide of the Human Melanoma Antigen Melan-A / MART-1 To A Peptide-Specific HLA-A * 0201 + Cytotoxic Cell Line," J Immunol , 157: 787-797 (1996 ); Rivoltini, L., et al ., "Binding and Presentation of Peptides Derived From Melanoma Antigens MART-1 and Glycoprotein-100 by HLA-A2 Subtypes: Implications for Peptide-Based Immunotherapy," J Immunol 156: 3882-3891 (1996); Kawashima, I., "The Multi-Epitope Approach for Immunotherapy for Cancer: Identification of Several CTL Epitopes from Various Tumor-Associated Antigens Expressed on Solid Epithelial Tumors," Hum Immunol 59: 1-14 (1998)] .
[225] Example 6: Peptide Compositions for Prophylactic Use
[226] The vaccine composition of the present invention is used to prevent infection or treat cancer in humans. For example, polyepitopeptide epitope compositions containing multiple CTL and HTL epitopes are administered to a subject at risk of HCV infection. The composition is provided as a single lipidated polypeptide comprising multiple epitopes. The vaccine is administered with an aqueous carrier consisting of Freund's incomplete adjuvant. When administered in a human dose to a 70 kg patient, the dose of peptide for initial immunization is about 1 to about 50,000 μg. After the initial administration of the vaccine, booster administration at 4 weeks was followed by an assessment of the magnitude of the immune response in the patient using a technique to measure the presence of an epitope-specific CTL population in the PBMC sample. If necessary, an additional booster dose is administered. The composition has been found to be safe and efficacious as a prophylactic against HCV infection.
[227] Alternatively, polyepitopetic peptide compositions can be administered as nucleic acids according to methods known in the art and described herein.
[228] The above discussion is provided by way of explanation of the invention, not as a limitation of the invention. Other variations of the invention will be apparent to those skilled in the art and will be included in the appended claims. All publications, patents, and patent applications cited herein are provided herein by reference.
<110> Epimmune Inc.<120> Subunit vaccines with A2 supermotifs<130> 399632003540<150> US 60 / 264,969<151> 2001-01-29<150> US 09 / 935,476<151> 2001-08-22<160> 69<170> KopatentIn 1.71<210> 1<211> 14<212> PRT<213> Homo Sapiens<400> 1Gln Tyr Ile Lys Ala Asn Ser Lys Phe Ile Gly Ile Thr Glu 1 5 10<210> 2<211> 21<212> PRT<213> Homo Sapiens<400> 2Asp Ile Glu Lys Lys Ile Ala Lys Met Glu Lys Ala Ser Ser Val Phe 1 5 10 15Asn Val Val Asn Ser            20<210> 3<211> 17<212> PRT<213> Homo Sapiens<400> 3Tyr Gly Ala Val Asp Ser Ile Leu Gly Gly Val Ala Thr Tyr Gly Ala 1 5 10 15Ala<210> 4<211> 10<212> PRT<213> Homo Sapiens<400> 4Phe Leu Pro Ser Asp Tyr Phe Pro Ser Val 1 5 10<210> 5<211> 9<212> PRT<213> Homo Sapiens<400> 5Phe Thr Gln Ala Gly Tyr Pro Ala Leu 1 5<210> 6<211> 9<212> PRT<213> Homo Sapiens<400> 6Tyr Val Ile Lys Val Ser Ala Arg Val 1 5<210> 7<211> 10<212> PRT<213> Homo Sapiens<400> 7Phe Leu Pro Ser Asp Tyr Phe Pro Ser Val 1 5 10<210> 8<211> 9<212> PRT<213> Homo Sapiens<400> 8Tyr Leu Val Ala Tyr Gln Ala Thr Val 1 5<210> 9<211> 10<212> PRT<213> Homo Sapiens<400> 9Phe Leu Pro Ser Asp Tyr Phe Pro Ser Val 1 5 10<210> 10<211> 9<212> PRT<213> Homo Sapiens<400> 10Tyr Leu Val Ala Tyr Gln Ala Thr Val 1 5<210> 11<211> 9<212> PRT<213> Homo Sapiens<220><221> VARIANT<222> 1<223> Xaa = Y or K<400> 11Xaa Leu Val Ala Tyr Gln Ala Thr Val 1 5<210> 12<211> 9<212> PRT<213> Homo Sapiens<220><221> VARIANT<222> 2<223> Xaa = L or K<400> 12Tyr Xaa Val Ala Tyr Gln Ala Thr Val 1 5<210> 13<211> 9<212> PRT<213> Homo Sapiens<220><221> VARIANT<222> 3<223> Xaa = V or K<400> 13Tyr Leu Xaa Ala Tyr Gln Ala Thr Val 1 5<210> 14<211> 9<212> PRT<213> Homo Sapiens<220><221> VARIANT<222> 4<223> Xaa = A or K<400> 14Tyr Leu Val Xaa Tyr Gln Ala Thr Val 1 5<210> 15<211> 9<212> PRT<213> Homo Sapiens<220><221> VARIANT<222> 5<223> Xaa = Y or K<400> 15Tyr Leu Val Ala Xaa Gln Ala Thr Val 1 5<210> 16<211> 9<212> PRT<213> Homo Sapiens<220><221> VARIANT<222> 6<223> Xaa = Q or K<400> 16Tyr Leu Val Ala Tyr Xaa Ala Thr Val 1 5<210> 17<211> 9<212> PRT<213> Homo Sapiens<220><221> VARIANT<222> 7<223> Xaa = A or K<400> 17Tyr Leu Val Ala Tyr Gln Xaa Thr Val 1 5<210> 18<211> 9<212> PRT<213> Homo Sapiens<220><221> VARIANT<222> 8<223> Xaa = T or K<400> 18Tyr Leu Val Ala Tyr Gln Ala Xaa Val 1 5<210> 19<211> 9<212> PRT<213> Homo Sapiens<220><221> VARIANT<222> 9<223> Xaa = V or K<400> 19Tyr Leu Val Ala Tyr Gln Ala Thr Xaa 1 5<210> 20<211> 10<212> PRT<213> Homo Sapiens<400> 20Phe Leu Pro Ser Asp Tyr Phe Pro Ser Val 1 5 10<210> 21<211> 10<212> PRT<213> Homo Sapiens<220><221> VARIANT<222> 1<223> Xaa = F or K<400> 21Xaa Leu Pro Ser Asp Tyr Phe Pro Ser Val 1 5 10<210> 22<211> 10<212> PRT<213> Homo Sapiens<220><221> VARIANT<222> 2<223> Xaa = L or K<400> 22Phe Xaa Pro Ser Asp Tyr Phe Pro Ser Val 1 5 10<210> 23<211> 10<212> PRT<213> Homo Sapiens<220><221> VARIANT<222> 3<223> Xaa = P or K<400> 23Phe Leu Xaa Ser Asp Tyr Phe Pro Ser Val 1 5 10<210> 24<211> 10<212> PRT<213> Homo Sapiens<220><221> VARIANT<222> 4<223> Xaa = S or K<400> 24Phe Leu Pro Xaa Asp Tyr Phe Pro Ser Val 1 5 10<210> 25<211> 10<212> PRT<213> Homo Sapiens<220><221> VARIANT<222> 5<223> Xaa = D or K<400> 25Phe Leu Pro Ser Xaa Tyr Phe Pro Ser Val 1 5 10<210> 26<211> 10<212> PRT<213> Homo Sapiens<220><221> VARIANT<222> 6<223> Xaa = Y or K<400> 26Phe Leu Pro Ser Asp Xaa Phe Pro Ser Val 1 5 10<210> 27<211> 10<212> PRT<213> Homo Sapiens<220><221> VARIANT<222> 7<223> Xaa = F or K<400> 27Phe Leu Pro Ser Asp Tyr Xaa Pro Ser Val 1 5 10<210> 28<211> 10<212> PRT<213> Homo Sapiens<220><221> VARIANT<222> 8<223> Xaa = P or K<400> 28Phe Leu Pro Ser Asp Tyr Phe Xaa Ser Val 1 5 10<210> 29<211> 10<212> PRT<213> Homo Sapiens<220><221> VARIANT<222> 9<223> Xaa = S or K<400> 29Phe Leu Pro Ser Asp Tyr Phe Pro Xaa Val 1 5 10<210> 30<211> 10<212> PRT<213> Homo Sapiens<220><221> VARIANT<222> 10<223> Xaa = V or K<400> 30Phe Leu Pro Ser Asp Tyr Phe Pro Ser Xaa 1 5 10<210> 31<211> 9<212> PRT<213> Homo Sapiens<400> 31Ala Leu Ala Lys Ala Ala Ala Ala Val 1 5<210> 32<211> 8<212> PRT<213> Homo Sapiens<220><221> VARIANT<222> 1Xaa = Any amino acid<221> VARIANT<222> 2Xaa = L, I, V, M, A, T, or Q<221> VARIANT(222) (3) ... (7)Xaa = Any amino acid<221> VARIANT<222> 8Xaa = L, I, V, M, A, or T<400> 32Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 1 5<210> 33<211> 9<212> PRT<213> Homo Sapiens<220><221> VARIANT<222> 1Xaa = Any amino acid<221> VARIANT<222> 2Xaa = L, I, V, M, A, T, or Q<221> VARIANT(222) (3) ... (8)Xaa = Any amino acid<221> VARIANT<222> 9Xaa = L, I, V, M, A, or T<400> 33Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 1 5<210> 34<211> 10<212> PRT<213> Homo Sapiens<220><221> VARIANT<222> 1Xaa = Any amino acid<221> VARIANT<222> 2Xaa = L, I, V, M, A, T, or Q<221> VARIANT(222) (3) ... (9)Xaa = Any amino acid<221> VARIANT<222> 10Xaa = L, I, V, M, A, or T<400> 34Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 1 5 10<210> 35<211> 11<212> PRT<213> Homo Sapiens<220><221> VARIANT<222> 1Xaa = Any amino acid<221> VARIANT<222> 2Xaa = L, I, V, M, A, T, or Q<221> VARIANT<222> (3) ... (10)Xaa = Any amino acid<221> VARIANT<222> 11Xaa = L, I, V, M, A, or T<400> 35Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 1 5 10<210> 36<211> 8<212> PRT<213> Homo Sapiens<220><221> VARIANT<222> 1Xaa = Any amino acid<221> VARIANT<222> 2Xaa = V, A, T, or Q<221> VARIANT(222) (3) ... (7)Xaa = Any amino acid<221> VARIANT<222> 8Xaa = L, I, V, M, A, or T<400> 36Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 1 5<210> 37<211> 9<212> PRT<213> Homo Sapiens<220><221> VARIANT<222> 1Xaa = Any amino acid<221> VARIANT<222> 2Xaa = V, A, T, or Q<221> VARIANT(222) (3) ... (8)Xaa = Any amino acid<221> VARIANT<222> 9Xaa = L, I, V, M, A, or T<400> 37Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 1 5<210> 38<211> 10<212> PRT<213> Homo Sapiens<220><221> VARIANT<222> 1Xaa = Any amino acid<221> VARIANT<222> 2Xaa = V, A, T, or Q<221> VARIANT(222) (3) ... (9)Xaa = Any amino acid<221> VARIANT<222> 10Xaa = L, I, V, M, A, or T<400> 38Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 1 5 10<210> 39<211> 11<212> PRT<213> Homo Sapiens<220><221> VARIANT<222> 1Xaa = Any amino acid<221> VARIANT<222> 2Xaa = V, A, T, or Q<221> VARIANT<222> (3) ... (10)Xaa = Any amino acid<221> VARIANT<222> 11Xaa = L, I, V, M, A, or T<400> 39Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 1 5 10<210> 40<211> 8<212> PRT<213> Homo Sapiens<220><221> VARIANT<222> 1Xaa = Any amino acid<221> VARIANT<222> 2Xaa = L, I, M, or Q<221> VARIANT(222) (3) ... (7)Xaa = Any amino acid<221> VARIANT<222> 8Xaa = L, I, V, M, A, or T<400> 40Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 1 5<210> 41<211> 9<212> PRT<213> Homo Sapiens<220><221> VARIANT<222> 1Xaa = Any amino acid<221> VARIANT<222> 2Xaa = L, I, M, or Q<221> VARIANT(222) (3) ... (8)Xaa = Any amino acid<221> VARIANT<222> 9Xaa = L, I, V, M, A, or T<400> 41Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 1 5<210> 42<211> 10<212> PRT<213> Homo Sapiens<220><221> VARIANT<222> 1Xaa = Any amino acid<221> VARIANT<222> 2Xaa = L, I, M, or Q<221> VARIANT(222) (3) ... (9)Xaa = Any amino acid<221> VARIANT<222> 10Xaa = L, I, V, M, A, or T<400> 42Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 1 5 10<210> 43<211> 11<212> PRT<213> Homo Sapiens<220><221> VARIANT<222> 1Xaa = Any amino acid<221> VARIANT<222> 2Xaa = L, I, M, or Q<221> VARIANT<222> (3) ... (10)Xaa = Any amino acid<221> VARIANT<222> 11Xaa = L, I, V, M, A, or T<400> 43Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 1 5 10<210> 44<211> 8<212> PRT<213> Homo Sapiens<220><221> VARIANT<222> 1Xaa = Any amino acid<221> VARIANT<222> 2<223> Xaa = I or Q<221> VARIANT(222) (3) ... (7)Xaa = Any amino acid<221> VARIANT<222> 8Xaa = L, I, V, M, A, or T<400> 44Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 1 5<210> 45<211> 9<212> PRT<213> Homo Sapiens<220><221> VARIANT<222> 1Xaa = Any amino acid<221> VARIANT<222> 2<223> Xaa = I or Q<221> VARIANT(222) (3) ... (8)Xaa = Any amino acid<221> VARIANT<222> 9Xaa = L, I, V, M, A, or T<400> 45Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 1 5<210> 46<211> 10<212> PRT<213> Homo Sapiens<220><221> VARIANT<222> 1Xaa = Any amino acid<221> VARIANT<222> 2<223> Xaa = I or Q<221> VARIANT(222) (3) ... (9)Xaa = Any amino acid<221> VARIANT<222> 10Xaa = L, I, V, M, A, or T<400> 46Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 1 5 10<210> 47<211> 11<212> PRT<213> Homo Sapiens<220><221> VARIANT<222> 1Xaa = Any amino acid<221> VARIANT<222> 2<223> Xaa = I or Q<221> VARIANT<222> (3) ... (10)Xaa = Any amino acid<221> VARIANT<222> 11Xaa = L, I, V, M, A, or T<400> 47Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 1 5 10<210> 48<211> 8<212> PRT<213> Homo Sapiens<220><221> VARIANT<222> 1Xaa = Any amino acid<221> VARIANT<222> 2Xaa = L, I, V, M, A, T, or Q<221> VARIANT(222) (3) ... (7)Xaa = Any amino acid<221> VARIANT<222> 8Xaa = L, I, V, M, A, or T<400> 48Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 1 5<210> 49<211> 9<212> PRT<213> Homo Sapiens<220><221> VARIANT<222> 1Xaa = Any amino acid<221> VARIANT<222> 2Xaa = L, I, V, M, A, T, or Q<221> VARIANT(222) (3) ... (8)Xaa = Any amino acid<221> VARIANT<222> 9Xaa = L, I, V, M, A, or T<400> 49Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 1 5<210> 50<211> 10<212> PRT<213> Homo Sapiens<220><221> VARIANT<222> 1Xaa = Any amino acid<221> VARIANT<222> 2Xaa = L, I, V, M, A, T, or Q<221> VARIANT(222) (3) ... (9)Xaa = Any amino acid<221> VARIANT<222> 10Xaa = L, I, V, M, A, or T<400> 50Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 1 5 10<210> 51<211> 11<212> PRT<213> Homo Sapiens<220><221> VARIANT<222> 1Xaa = Any amino acid<221> VARIANT<222> 2Xaa = L, I, V, M, A, T, or Q<221> VARIANT<222> (3) ... (10)Xaa = Any amino acid<221> VARIANT<222> 11Xaa = L, I, V, M, A, or T<400> 51Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 1 5 10<210> 52<211> 8<212> PRT<213> Homo Sapiens<220><221> VARIANT<222> 1Xaa = Any amino acid<221> VARIANT<222> 2Xaa = L, I, V, M, A, T, or Q<221> VARIANT(222) (3) ... (7)Xaa = Any amino acid<221> VARIANT<222> 8<223> Xaa = T<400> 52Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 1 5<210> 53<211> 9<212> PRT<213> Homo Sapiens<220><221> VARIANT<222> 1Xaa = Any amino acid<221> VARIANT<222> 2Xaa = L, I, V, M, A, T, or Q<221> VARIANT(222) (3) ... (8)Xaa = Any amino acid<221> VARIANT<222> 9<223> Xaa = T<400> 53Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 1 5<210> 54<211> 10<212> PRT<213> Homo Sapiens<220><221> VARIANT<222> 1Xaa = Any amino acid<221> VARIANT<222> 2Xaa = L, I, V, M, A, T, or Q<221> VARIANT(222) (3) ... (9)Xaa = Any amino acid<221> VARIANT<222> 10<223> Xaa = T<400> 54Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 1 5 10<210> 55<211> 11<212> PRT<213> Homo Sapiens<220><221> VARIANT<222> 1Xaa = Any amino acid<221> VARIANT<222> 2Xaa = L, I, V, M, A, T, or Q<221> VARIANT<222> (3) ... (10)Xaa = Any amino acid<221> VARIANT<222> 11<223> Xaa = T<400> 55Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 1 5 10<210> 56<211> 8<212> PRT<213> Homo Sapiens<220><221> VARIANT<222> 1Xaa = D, E, or P<221> VARIANT<222> 2Xaa = L, M, I, V, A, T, or Q<221> VARIANT<222> 3Xaa = G, R, H, or K<221> VARIANT<222> 4Xaa = Any amino acid<221> VARIANT<222> 5Xaa = L, I, V, M, Y, F, or W<221> VARIANT<222> 6Xaa = A, Y, F, or W<221> VARIANT<222> (7) ... (7)<223> Xaa = G or P<221> VARIANT<222> (8) ... (8)Xaa = V, L, I, V, A, T<400> 56Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 1 5<210> 57<211> 9<212> PRT<213> Homo Sapiens<220><221> VARIANT<222> 1Xaa = F, Y, D, E, P, or Q<221> VARIANT<222> 2L, M, I, V, A, T, or Q<221> VARIANT<222> 3<223> M, F, W, Y, E, R, or K<221> VARIANT<222> 4<223> W or M<221> VARIANT<222> 5<223> H, Y, E, or N<221> VARIANT<222> 6<223> R, H, or K<221> VARIANT<222> (7) ... (7)Xaa = F, W, Y, D, E, R, K, or G<221> VARIANT<222> (8) ... (8)<223> Xaa = F, M or V<221> VARIANT(222) (9) ... (9)Xaa = V, L, I, V, A, or T<400> 57Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 1 5<210> 58<211> 10<212> PRT<213> Homo Sapiens<220><221> VARIANT<222> 1Xaa = F, Y, D, E, P, or Q<221> VARIANT<222> 2Xaa = L, M, I, V, A, T, or Q<221> VARIANT<222> 3Xaa = L, I, M, F, Y, R, K, or E<221> VARIANT<222> 4<223> Xaa = W or Q<221> VARIANT<222> 5Xaa = F, W, R, K, or E<221> VARIANT<222> 6Xaa = Any amino acid<221> VARIANT<222> (7) ... (7)<223> Xaa = L or R<221> VARIANT<222> (8) ... (8)Xaa = M, F, W, D, N, Q, R, or K<221> VARIANT(222) (9) ... (9)<223> Xaa = F<221> VARIANT<222> (10) ... (10)Xaa = V, L, I, V, A, or T<400> 58Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 1 5 10<210> 59<211> 11<212> PRT<213> Homo Sapiens<220><221> VARIANT<222> 1Xaa = L, I, V, M, R, H, K, G, D, E, Q, N, P<221> VARIANT<222> 2Xaa = L, M, I, V, T, or Q<221> VARIANT<222> 3Xaa = L, I V, M, Y, F, W, G, Q, N, S, T, or C<221> VARIANT<222> 4Xaa = D, E, S, T, or C<221> VARIANT<222> 5Xaa = G, R, H, or K<221> VARIANT<222> 6Xaa = L, I, V, M, G, D, E, R, H, K, Y, F, W, or P<221> VARIANT<222> (7) ... (7)Xaa = G, D, E, Q, or N<221> VARIANT<222> (8) ... (8)Xaa = Y, F, W, G, D, E, or A<221> VARIANT(222) (9) ... (9)Xaa = Y, F, W, L, I, V, M, D, E, R, H, K, or P<221> VARIANT<222> (10) ... (10)Xaa = P, G, Y, F, W, R, H, K, Q, or N<221> VARIANT<222> (11) ... (11)Xaa = V, L, I, V, A, or T<400> 59Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 1 5 10<210> 60<211> 9<212> PRT<213> Homo Sapiens<220><221> VARIANT<222> 1Xaa = D, E, S, T, or C<221> VARIANT<222> 2Xaa = Q, V, T, I, A, M, or L<221> VARIANT<222> 3Xaa = A, D, or E<221> VARIANT<222> 4<223> Xaa = Q or N<221> VARIANT<222> 5<223> Xaa = G<221> VARIANT<222> 6<223> Xaa = A or P<221> VARIANT<222> (7) ... (7)<223> Xaa = D or E<221> VARIANT<222> (8) ... (8)Xaa = Any amino acid<221> VARIANT(222) (9) ... (9)Xaa = I, V, L, A, M, or T<400> 60Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 1 5<210> 61<211> 10<212> PRT<213> Homo Sapiens<220><221> VARIANT<222> 1Xaa = Q, N, Y, F, W, D, E, G, S, T, or C<221> VARIANT<222> 2Xaa = Q, V, T, I, A, M, or L<221> VARIANT<222> 3Xaa = Y, F, W, D, E, or G<221> VARIANT<222> 4Xaa = S, T, C, or P<221> VARIANT<222> 5<223> Xaa = D or E<221> VARIANT<222> 6Xaa = A, D, E, R, H, or K<221> VARIANT<222> (7) ... (7)Xaa = L, I, V, M, P, G, Q, or N<221> VARIANT<222> (8) ... (8)Xaa = R, H, K, D, or E<221> VARIANT(222) (9) ... (9)Xaa = P, R, H, or K<221> VARIANT<222> (10) ... (10)Xaa = I, V, L, A, M, or T<400> 61Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 1 5 10<210> 62<211> 9<212> PRT<213> Homo Sapiens<220><221> VARIANT<222> 1<223> Xaa = Y, F, W, or P<221> VARIANT<222> 2Xaa = L, M, Q, V, A, I, or T<221> VARIANT<222> 3Xaa = A, R, H, K, D, or E<221> VARIANT<222> 4Xaa = Any amino acid<221> VARIANT<222> 5<223> Xaa = D or E<221> VARIANT<222> 6<223> Xaa = Y, F, or W<221> VARIANT<222> (7) ... (7)Xaa = G, A, Y, F, or W<221> VARIANT<222> (8) ... (8)Xaa = P, R, H, or K<221> VARIANT(222) (9) ... (9)Xaa = V, I, T, A, M, or L<400> 62Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 1 5<210> 63<211> 9<212> PRT<213> Homo Sapiens<220><221> VARIANT<222> 1Xaa = Y, F, W, Q, N, D, E, L, I, V, M, or P<221> VARIANT<222> 2Xaa = L, M, Q, V, A, T, or I<221> VARIANT<222> 3Xaa = Y, F, W, R, H, K, S, T, C, D, E, or G<221> VARIANT<222> 4Xaa = D, E, or P<221> VARIANT<222> 5<223> Xaa = A<221> VARIANT<222> 6<223> Xaa = P<221> VARIANT<222> (7) ... (7)Xaa = L, I, V, M, P, G, Q, or N<221> VARIANT<222> (8) ... (8)Xaa = G, D, E, R, H, K, Y, F, or W<221> VARIANT(222) (9) ... (9)Xaa = A, R, H, or K<221> VARIANT<222> (10) ... (10)Xaa = V, I, T, A, M, or L<400> 63Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 1 5<210> 64<211> 8<212> PRT<213> Homo Sapiens<220><221> VARIANT<222> 1<223> Xaa = P<221> VARIANT<222> 2Xaa = Q, V, A, I, T, M, or L<221> VARIANT<222> 3Xaa = L, I, V, M, G, R, H, or K<221> VARIANT<222> 4Xaa = Q, N, or P<221> VARIANT<222> 5<223> Xaa = G or P<221> VARIANT<222> 6<223> Xaa = A or P<221> VARIANT<222> (7) ... (7)<223> Xaa = D or E<221> VARIANT<222> (8) ... (8)<223> Xaa = Y, F, or W<221> VARIANT(222) (9) ... (9)Xaa = V, I, L, A, T, or M<400> 64Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 1 5<210> 65<211> 9<212> PRT<213> Homo Sapiens<220><221> VARIANT<222> 1Xaa = Q, N, D, E, or P<221> VARIANT<222> 2Xaa = Q, V, A, I, T, M, or L<221> VARIANT<222> 3Xaa = Y, F, W, L, I, V, M, G, D, E, R, H, K, Q, N,      S, T, or C<221> VARIANT<222> 4Xaa = Any amino acid<221> VARIANT<222> 5<223> Xaa = D or E<221> VARIANT<222> 6<223> Xaa = D or E<221> VARIANT<222> (7) ... (7)Xaa = L, I, V, M, P, A, Q, or N<221> VARIANT<222> (8) ... (8)Xaa = R, H, K, Q, or N<221> VARIANT(222) (9) ... (9)Xaa = A, D, E, P, R, H, or K<221> VARIANT<222> (10) ... (10)Xaa = V, I, L, A, T, or M<400> 65Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 1 5<210> 66<211> 8<212> PRT<213> Homo Sapiens<220><221> VARIANT<222> 1Xaa = Y, F, W, D, E, G, R, H, or K<221> VARIANT<222> 2Xaa = V, T, A, I, or M<221> VARIANT<222> 3Xaa = A, G, R, H, K, D, or E<221> VARIANT<222> 4Xaa = Any amino acid<221> VARIANT<222> 5X 223 = P, D, or E<221> VARIANT<222> 6Xaa = R, H, K, or A<221> VARIANT<222> (7) ... (7)Xaa = A, R, H, or K<221> VARIANT<222> (8) ... (8)Xaa = Any amino acid<221> VARIANT(222) (9) ... (9)Xaa = V, I, L, A, M, or T<400> 66Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 1 5<210> 67<211> 9<212> PRT<213> Homo Sapiens<220><221> VARIANT<222> 1Xaa = P, Q, N, D, E, or G<221> VARIANT<222> 2Xaa = V, T, A, I, or M<221> VARIANT<222> 3Xaa = A, R, H, K, P, Q, N, G, D, or E<221> VARIANT<222> 4Xaa = A, D, E, R, H, K, or P<221> VARIANT<222> 5Xaa = D, E, Q, N, P, S, T, or C<221> VARIANT<222> 6Xaa = Q, N, R, H, or K<221> VARIANT<222> (7) ... (7)Xaa = Q, N, Y, F, W, R, H, K, D, E, P, S, T, or C<221> VARIANT<222> (8) ... (8)Xaa = R, H, K, D, E, Q, or N<221> VARIANT(222) (9) ... (9)Xaa = Any amino acid<221> VARIANT<222> (10) ... (10)Xaa = V, I, L, A, M, or T<400> 67Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 1 5<210> 68<211> 9<212> PRT<213> Homo Sapiens<220><221> VARIANT<222> 1Xaa = Y, F, or P<221> VARIANT<222> 2Xaa = L, M, V, T, Q, A, or I<221> VARIANT<222> 3Xaa = A, R, K, D, or E<221> VARIANT<222> 4Xaa = Any amino acid<221> VARIANT<222> 5<223> Xaa = E<221> VARIANT<222> 6<223> Xaa = A<221> VARIANT<222> (7) ... (7)<223> Xaa = D or E<221> VARIANT<222> (8) ... (8)Xaa = Any amino acid<221> VARIANT(222) (9) ... (9)Xaa = I, V, L, M, T, or A<400> 68Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 1 5<210> 69<211> 10<212> PRT<213> Homo Sapiens<220><221> VARIANT<222> 1Xaa = F, Y, D, E, or P<221> VARIANT<222> 2Xaa = L, M, V, T, Q, A, or I<221> VARIANT<222> 3Xaa = F, Y, W, R, K, D, E, or G<221> VARIANT<222> 4<223> Xaa = P<221> VARIANT<222> 5<223> Xaa = D or E<221> VARIANT<222> 6Xaa = Any amino acid<221> VARIANT<222> (7) ... (7)Xaa = L, I, V, M, Q, N, or P<221> VARIANT<222> (8) ... (8)Xaa = H, R, K, D, Q, or N<221> VARIANT(222) (9) ... (9)<223> Xaa = R, H, or K<221> VARIANT<222> (10) ... (10)Xaa = V, I, L, M, T, or A<400> 69Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 1 5 10

权利要求:
Claims (28)
[1" claim-type="Currently amended] Consisting of 8 to 11 amino acids and the amino acid at position 2 from the N-terminus is L, I, V, M, A, T, or Q, and the C-terminal amino acid is L, I, V, M, A or T Three or more HLAs encoded by A * 0201, A * 0202, A * 0203, A * 0204, A * 0205, A * 0206, A * 0207, A * 6802, and A * 6901 alleles. Contacting the molecule;
Measuring an IC ₅₀ value; And
A method for identifying a HLA-A2 super motif restricted peptide, comprising identifying a peptide that binds three or more HLA molecules with an IC ₅₀ value of less than 500 nM as an HLA-A2 super motif restricted peptide.
[2" claim-type="Currently amended] The method of claim 1 wherein the amino acid at position 2 of the peptide is V, A, T or Q.
[3" claim-type="Currently amended] 2. The method of claim 1 wherein the amino acid at position 2 of the peptide is L, I, M or Q.
[4" claim-type="Currently amended] 2. The method of claim 1 wherein the amino acid at position 2 of the peptide is I or Q.
[5" claim-type="Currently amended] The method of claim 1 wherein the C-terminal amino acid is L, I, V, M, A or T.
[6" claim-type="Currently amended] 2. The method of claim 1 wherein the C-terminal amino acid is T.
[7" claim-type="Currently amended] The method of claim 1, wherein the peptide is HIV antigen, HBV antigen, HCV antigen, HPV antigen, PSA antigen, Epstein-Barr virus antigen, KSHV antigen, Lassa virus antigen, MT antigen, p53 antigen, CEA antigen, A method derived from a TSA antigen, a MAGE antigen, or a Her2 / neu antigen.
[8" claim-type="Currently amended] Consisting of 8 to 11 amino acids, the amino acid at position 2 from the N-terminus is L, I, V, M, A, T, or Q and the C-terminal amino acid is L, I, V, M, A or T And peptides forming the peptide / HLA-A2 complex, A * 0201, A * 0202, A * 0203, A * 0204, A * 0205, A * 0206, A * 0207, A * 6802, and A * 6901 Contacting with at least three HLA molecules encoded by the allele;
Determining whether the peptide / HLA-A2 complex induces a CTL response; And
A method for identifying an immunogenic HLA-A2 super motif restricted peptide, comprising identifying a peptide that induces a CTL response in a complex with at least three HLAs as an HLA-A2 super motif restricted peptide.
[9" claim-type="Currently amended] The method of claim 8, wherein the amino acid at position 2 of the peptide is V, A, T or Q.
[10" claim-type="Currently amended] The method of claim 8, wherein the amino acid at position 2 of the peptide is L, I, M or Q. 10.
[11" claim-type="Currently amended] The method of claim 8, wherein the amino acid at position 2 of the peptide is I or Q. 10.
[12" claim-type="Currently amended] The method of claim 8, wherein the C-terminal amino acid is L, I, V, M, A or T. 10.
[13" claim-type="Currently amended] The method of claim 8, wherein the C-terminal amino acid is T. 10.
[14" claim-type="Currently amended] The method of claim 8, wherein the peptide is HIV antigen, HBV antigen, HCV antigen, HPV antigen, PSA antigen, Epstein-Barr virus antigen, KSHV antigen, Lassa virus antigen, MT antigen, p53 antigen, CEA antigen, A method derived from a TSA antigen, a MAGE antigen, or a Her2 / neu antigen.
[15" claim-type="Currently amended] Providing an amino acid sequence of the antigen of interest;
Within this sequence, the amino acid at position 2 from the N-terminus is L, I, V, M, A, T, or Q and the C-terminal amino acid is L, I, V, M Identifying a putative T-cell epitope that is A or T;
Preparing one or more peptide fragments of the antigen of interest comprising said epitope;
3 or more HLA molecules encoded by the peptides A * 0201, A * 0202, A * 0203, A * 0204, A * 0205, A * 0206, A * 0207, A * 6802, and A * 6901 alleles Contacting with;
Measuring an IC ₅₀ value; And
Selecting a peptide that binds three or more HLA molecules with an IC ₅₀ value of less than 500 nM as the HLA-A2 super motif restricted peptide.
[16" claim-type="Currently amended] The method of claim 15, wherein the amino acid at position 2 of the peptide is V, A, T or Q.
[17" claim-type="Currently amended] The method of claim 15, wherein the amino acid at position 2 of the peptide is L, I, M or Q.
[18" claim-type="Currently amended] The method of claim 15, wherein the amino acid at position 2 of the peptide is I or Q. 16.
[19" claim-type="Currently amended] The method of claim 15, wherein the C-terminal amino acid is L, I, V, M, A or T.
[20" claim-type="Currently amended] The method of claim 15, wherein the C-terminal amino acid is T.
[21" claim-type="Currently amended] The method of claim 15, wherein the antigen is HIV, HBV, HCV, HPV, PSA, Epstein-Barr virus, KSHV, Lassa virus, MT, p53, CEA, TSA, MAGE, or Her2 / neu.
[22" claim-type="Currently amended] Providing an amino acid sequence of the antigen of interest;
Within this sequence, the amino acid at position 2 from the N-terminus is L, I, V, M, A, T, or Q and the C-terminal amino acid is L, I, V, M Identifying a putative T-cell epitope that is A or T;
Preparing one or more peptide fragments of the antigen of interest comprising said epitope;
Determining whether the peptide / HLA-A2 complex induces a CTL response; And
Selecting a peptide that induces CTL in complex with at least three HLAs as the HLA-A2 supermotifie restricted peptide, wherein the immunogenic HLA-A2 supermotifie restricted peptide is prepared.
[23" claim-type="Currently amended] The method of claim 22, wherein the amino acid at position 2 of the peptide is V, A, T or Q.
[24" claim-type="Currently amended] The method of claim 22, wherein the amino acid at position 2 of the peptide is L, I, M or Q.
[25" claim-type="Currently amended] 23. The method of claim 22, wherein the amino acid at position 2 of the peptide is I or Q.
[26" claim-type="Currently amended] The method of claim 22, wherein the C-terminal amino acid is L, I, V, M, A or T.
[27" claim-type="Currently amended] The method of claim 22, wherein the C-terminal amino acid is T.
[28" claim-type="Currently amended] The method of claim 22, wherein the antigen is HIV, HBV, HCV, HPV, PSA, Epstein-Barr virus, KSHV, Lassa virus, MT, p53, CEA, TSA, MAGE, or Her2 / neu.

类似技术:

---

公开号 | 公开日 | 专利标题

---

US9534030B2|2017-01-03|Survivin-derived peptides and uses thereof

---

JP6435286B2|2018-12-05|Cancer vaccine composition

---

Lang et al.2001|HLA-A2 restricted, melanocyte-specific CD8+ T lymphocytes detected in vitiligo patients are related to disease activity and are predominantly directed against MelanA/MART1

---

FI123050B|2012-10-15|Melanoma antigens

---

US9913884B2|2018-03-13|HLA-A2 tumor associated antigen peptides and compositions

---

Tsai et al.1997|Identification of subdominant CTL epitopes of the GP100 melanoma-associated tumor antigen by primary in vitro immunization with peptide-pulsed dendritic cells.

---

Rehermann et al.1995|The cytotoxic T lymphocyte response to multiple hepatitis B virus polymerase epitopes during and after acute viral hepatitis.

---

DE69533594T2|2006-02-16|Preparations and method for triggering ctl immunity

---

Bullock et al.2000|The density of peptides displayed by dendritic cells affects immune responses to human tyrosinase and gp100 in HLA-A2 transgenic mice

---

DE69723434T2|2004-05-19|Method for selection and production of t-cell peptide epitope and vaccine with this epitope

---

Sarobe et al.1998|Enhanced in vitro potency and in vivo immunogenicity of a CTL epitope from hepatitis C virus core protein following amino acid replacement at secondary HLA-A2. 1 binding positions.

---

EP1078092B1|2011-08-03|Expression vectors for stimulating an immune response and methods of using the same

---

Bakker et al.1997|Analogues of CTL epitopes with improved MHC class‐I binding capacity elicit anti‐melanoma CTL recognizing the wild‐type epitope

---

Lauvau et al.1999|Human transporters associated with antigen processing | select epitope precursor peptides for processing in the endoplasmic reticulum and presentation to T cells

---

US5736142A|1998-04-07|Alteration of immune response using pan DR-binding peptides

---

van der Most et al.1996|Analysis of cytotoxic T cell responses to dominant and subdominant epitopes during acute and chronic lymphocytic choriomeningitis virus infection.

---

Bertoni et al.1997|Human histocompatibility leukocyte antigen-binding supermotifs predict broadly cross-reactive cytotoxic T lymphocyte responses in patients with acute hepatitis.

---

Gairin et al.1995|Optimal lymphocytic choriomeningitis virus sequences restricted by H-2Db major histocompatibility complex class I molecules and presented to cytotoxic T lymphocytes.

---

US20080107668A1|2008-05-08|Cytotoxic t-lymphocyte-inducing immunogens for prevention, treatment, and diagnosis of cancer

---

Pogue et al.1995|Amino-terminal alteration of the HLA-A* 0201-restricted human immunodeficiency virus pol peptide increases complex stability and in vitro immunogenicity

---

JP3694299B2|2005-09-14|Peptides that induce the response of cytotoxic T lymphocytes to hepatitis B virus

---

US20130017253A1|2013-01-17|Inducing Cellular Immune Responses to Human Papillomavirus Using Peptide and Nucleic Acid Compositions

---

Lu et al.2004|Multiepitope Trojan antigen peptide vaccines for the induction of antitumor CTL and Th immune responses

---

US7220420B2|2007-05-22|Hepatitis C virus-derived peptides capable of inducing cytotoxic T lymphocyte responses

---

T Snyder et al.2003|Molecular mechanisms and biological significance of CTL avidity

同族专利:

---

公开号 | 公开日

---

IL156660D0|2004-01-04|

---

NZ526860A|2007-03-30|

---

US20040096445A1|2004-05-20|

---

WO2002061435A3|2003-07-10|

---

WO2002061435A2|2002-08-08|

---

CZ20032054A3|2003-12-17|

---

CA2432995A1|2002-08-08|

---

MXPA03006581A|2004-06-25|

---

CN1653337A|2005-08-10|

---

AU2002243730B2|2007-07-12|

---

JP2005512016A|2005-04-28|

---

RU2003126447A|2005-02-27|

---

SK9512003A3|2003-12-02|

---

CA2432995C|2011-07-26|

---

EP1368659A2|2003-12-10|

引用文献:

---

公开号 | 申请日 | 公开日 | 申请人 | 专利标题

---

法律状态:
2001-01-29|Priority to US26496901P

---

2001-01-29|Priority to US60/264,969

---

2001-08-22|Priority to US09/935,476

---

2001-08-22|Priority to US09/935,476

---

2002-01-29|Application filed by 에피뮨 인코포레이티드

---

2002-01-29|Priority to PCT/US2002/002708

---

2004-06-23|Publication of KR20040052475A

优先权:

---

申请号 | 申请日 | 专利标题

---

US26496901P| true| 2001-01-29|2001-01-29|

---

US60/264,969|2001-01-29|

---

US09/935,476|2001-08-22|

---

US09/935,476|US20040096445A1|1999-06-30|2001-08-22|Subunit vaccines with A2 supermotifs|

---

PCT/US2002/002708|WO2002061435A2|2001-01-29|2002-01-29|Subunit vaccines with a2 supermotifs|